Full-length Review

Piracetam and other structurally related nootropics

Alex Haahr Gouliaev a, Alexander Senning b,*

* Department of Chemistry, Aarhus University, Langelandsgade 140, DK-8000 Aarhus C, Denmark, b Department of Chemistry and Chemical Engineering, The Engineering Academy of Denmark, Building 376, DK-2800 Lyngby, Denmark

(Accepted 17 August 1993)

Contents

Summary .......................................................................................................................... 182
1. Introduction .................................................................................................................. 182
2. The most investigated compounds ............................................................................. 183
  2.1. Piracetam .................................................................................................................. 185
    2.1.1. Chemical, bibliographic and historical data ......................................................... 185
    2.1.2. Clinical findings .................................................................................................. 187
    2.1.3. Pharmacokinetics ............................................................................................... 187
    2.1.4. Antiamnesic and memory-enhancing properties of piracetam .............................. 188
    2.1.5. Interaction with γ-aminobutyric acid neurotransmission .................................... 188
    2.1.6. Interaction with glutamate neurotransmission ...................................................... 188
    2.1.7. Interaction with acetylcholine neurotransmission ................................................. 189
    2.1.8. Interaction with noradrenaline/dopamine/5-hydroxytryptamine neurotransmission ................................................................. 189
    2.1.9. Interaction with steroids ...................................................................................... 190
    2.1.10. Interaction with protein/lipid metabolism ........................................................... 190
    2.1.11. Other effects ..................................................................................................... 190
  2.2. Analogues of piracetam ............................................................................................ 191
    2.2.1. Substituted 2-oxopyrrolidineacetamides ............................................................. 191
    2.2.2. 2-Oxopyrrolidineacetic acid, its hydrazide and ester derivatives ......................... 191
    2.2.3. Amidines and amidoximes of piracetam ............................................................... 191
    2.2.4. 2-Oxopyrrolidine derivatives .............................................................................. 191
    2.2.5. Thiocarbonyl analogues ...................................................................................... 191
    2.2.6. Cyclo- and side-chain-modified homologues ...................................................... 191
    2.2.7. Tacrine analogues ............................................................................................... 191
    2.2.8. Peptide analogues .............................................................................................. 191
    2.2.9. Proline-

0165-0173/94/$07.00 © 1994 Elsevier Science B.V. All rights reserved
SSDI 0165-0173(93)E0013-2
2.4. Analogues of oxiracetam ................................................................. 196
  2.4.1. 4-Alkoxo-/4-acyloxy-2-oxopyrrolidinaceitic acid derivatives ........... 196
  2.4.2. 3-Hydroxy-analogues of oxiracetam .......................................... 197

2.5. Pramiracetam ................................................................................. 197
  2.5.1. Chemical, bibliographic and historical data .................................. 197
  2.5.2. Clinical findings ........................................................................ 197
  2.5.3. Pharmacokinetics .................................................................... 197
  2.5.4. Antiamnesic and memory-enhancing properties of pramiracetam .... 197
  2.5.5. Interaction with γ-aminobutyric acid neurotransmission ............... 197
  2.5.6. Interaction with acetylcholine neurotransmission ......................... 197
  2.5.7. Interaction with noradrenaline/dopamine/5-hydroxytryptamine neurotransmission ................................................................. 198
  2.5.8. Interaction with steroids ............................................................ 198
  2.5.9. Other effects ............................................................................ 198

2.6. Analogues of pramiracetam ............................................................. 198

2.7. Etiracetam ...................................................................................... 199
  2.7.1. Chemical, bibliographic and historical data .................................. 199
  2.7.2. Antianemsic and memory-enhancing properties of etiracetam ....... 199
  2.7.3. Interaction with acetylcholine neurotransmission ......................... 199
  2.7.4. Other effects ............................................................................ 199

2.8. Nefiracetam .................................................................................... 199
  2.8.1. Chemical, bibliographic and historical data .................................. 199
  2.8.2. Pharmacokinetics .................................................................... 200
  2.8.3. Antiamnesic and memory-enhancing properties of nefiracetam .... 200
  2.8.4. Interaction with γ-aminobutyric acid neurotransmission ............... 200
  2.8.5. Interaction with acetylcholine neurotransmission ......................... 201
  2.8.6. Interaction with noradrenaline/dopamine/5-hydroxytryptamine neurotransmission ................................................................. 201
  2.8.7. Interaction with protein/lipid metabolism ..................................... 201
  2.8.8. Other effects ............................................................................ 201

2.9. Aniracetam ..................................................................................... 201
  2.9.1. Chemical, bibliographic and historical data .................................. 201
  2.9.2. Clinical findings ........................................................................ 203
  2.9.3. Pharmacokinetics .................................................................... 203
  2.9.4. Antiamnesic and memory-enhancing properties of aniracetam ....... 203
  2.9.5. Interaction with γ-aminobutyric acid neurotransmission ............... 203
  2.9.6. Interaction with glutamate neurotransmission .............................. 203
  2.9.7. Interaction with acetylcholine neurotransmission ......................... 203
  2.9.8. Interaction with noradrenaline/dopamine/5-hydroxytryptamine neurotransmission ................................................................. 204
  2.9.9. Interaction with steroids ............................................................ 204
  2.9.10. Interaction with protein/lipid metabolism .................................... 204
  2.9.11. Other effects ........................................................................... 204

2.10. Analogues of aniracetam ............................................................... 204
  2.10.1. Phenyl-substituted analogues .................................................... 204
  2.10.2. 1-Acyl-2-pyrrolidinones ......................................................... 204
  2.10.3. 1-Sulfonyl-2-pyrrolidinones .................................................. 204
  2.10.4. Other analogues of aniracetam ................................................ 204

2.11. Rolziracetam .................................................................................. 204
  2.11.1. Chemical, bibliographic and historical data .................................. 204
  2.11.2. Pharmacokinetics .................................................................... 205
  2.11.3. Interaction with acetylcholine neurotransmission ......................... 205
  2.11.4. X-ray structure of rolziracetam ................................................ 205

2.12. Analogues of rolziracetam ............................................................ 205

3. General discussion ........................................................................... 205
  3.1. Structure–activity relationships ..................................................... 205
  3.2. Mechanisms of action .................................................................. 206
    3.2.1. Previously suggested mechanisms of action ............................... 206
    3.2.2. Modulation of ion fluxes, the mechanism of action? .................... 207
  3.3. Clinical potential ........................................................................ 209
  3.4. Final comments ........................................................................ 209

Acknowledgements .............................................................................. 210

Abbreviations ...................................................................................... 210
Abstract

Nearly three decades have now passed since the discovery of the piracetam-like nootropics, compounds which exhibit cognition-enhancing properties, but for which no commonly accepted mechanism of action has been established. This review covers clinical, pharmacokinetic, biochemical and behavioural results presented in the literature from 1965 through 1992 (407 references) of piracetam, oxiracetam, pramiracetam, etiracetam, nefiracetam, aniracetam and rolziracetam and their structural analogues. The piracetam-like nootropics are capable of achieving reversal of amnesia induced by, e.g., scopolamine, electroconvulsive shock and hypoxia. Protection against barbiturate intoxication is observed and some benefit in clinical studies with patients suffering from mild to moderate degrees of dementia has been demonstrated. No affinity for the $\alpha_1$, $\alpha_2$, $\beta$, muscarinic, 5-hydroxytryptamine-, dopamine, adenosine-$A_1$, $\mu$-opiate, $\gamma$-aminobutyric acid (GABA) (except for nefiracetam (GABA$_A$)), benzodiazepine and glutamate receptors has been found. The racetams possess a very low toxicity and lack serious side effects. Increased turnover of different neurotransmitters has been observed as well as other biochemical findings, e.g., inhibition of enzymes such as prolylendopeptidase. So far, no generally accepted mechanism of action has, however, emerged. We believe that the effect of the racetams is due to a potentiation of already present neurotransmission and that much evidence points in the direction of a modulated ion flux by, e.g., potentiated calcium influx through non-L-type voltage-dependent calcium channels, potentiated sodium influx through $\alpha$-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor gated channels or voltage-dependent channels or decreases in potassium efflux. Effects on carrier mediated ion transport are also possible.

Key words: Memory; Cognition; Nootropics; Piracetam derivative; Mechanism; Membrane excitability; Pharmacokinetics

1. Introduction

Almost thirty years have now passed since the discovery of the piracetam-like nootropics. The term nootropic was coined by Giurgea in 1972, from Greek foros (mind) and Greek tropus (turn), to describe the then newly discovered properties of these compounds: (1) enhancement of learning and memory; (2) facilitation of the flow of information between the cerebral hemispheres; (3) enhancement of the resistance towards chemical and physical injuries; and (4) lack of the usual psychological and general cardiovascular pharmacological activity of psychopharmaca.

A great deal of different biochemical and behavioural results have been reported for these compounds, the mechanism of action of these protective and cognition enhancing drugs having, however, not yet been elucidated.

The aim of the present review is therefore to summarise and discuss the biochemical events, behavioural events, pharmacokinetic properties and clinical results which have been reported and furthermore, to show the classes of chemical structures which, from 1965 to 1992, have been tested for nootropic properties. In doing this we hope to inspire research in the area of cognition enhancers, which hopefully will elucidate the mechanism of action of these compounds and lead to even more efficient compounds for the treatment of cognitive disorders.

This review has been prepared after perusal of the original literature in the case of core papers and of abstracts from Chemical Abstracts and Medline as far as more peripheral articles are concerned.

The information on piracetam presented consolidates the contents of previous reviews by others and the results of a CD-ROM Medline search covering the period 1991–1992. Literature on oxiracetam, pramiracetam, etiracetam, nefiracetam, aniracetam, rolziracetam and dupracetam has been retrieved through a CD-ROM Medline search covering the period 1983–1992. Additional material, also concerning analogues of the above-mentioned compounds, was retrieved by means of a Chemical Abstract online search (The Scientific and Technical Information Network (STN), File CAOLD, covering 1965–1967, and File CA, covering 1967–) based on the following substructure (1) (Fig. 1):

Altogether data concerning 1666 compounds (many of which contain the 2-oxopyrrolidinacetic acid derivative (racetam) substructure as part of a peptide sequence) were retrieved. Of these approximately 660 were deemed worthy of further consideration. Further supplementary information concerning chemical, bibliographic and historical data has been retrieved by searches in Martindale, Merck Index and finally Beilstein, Handbook of Organic Chemistry (ONLINE, DIALOG Base 390).

Thus, this review deals with most compounds corre-
Fig. 1. Substructure used for CA-ONLINE search.

sponding to the substructure plus additional subject matter referred to in the literature in our file. For practical reasons analogues of compounds such as aniracetam, rolziracetam and other compounds containing only the 2-pyrrolidinone moiety (but not a side chain analogous to that of piracetam) which have been tested for nootropic activity are briefly mentioned where appropriate, but not treated exhaustively.

Furthermore, non-racetams like tenilsetam have often been categorized together with the nootropics of the piracetam type regardless of their chemical dissimilarity. Such compounds lie outside the scope of this review.

Information on pre-1983 work with piracetam and oxiracetam has been located through previous reviews92-94,282,333,345,391 and is only treated through these (see also the nootropil monography364). For general reviews on cognition enhancers see refs. 74,198,256,283,320 and especially Fröstl and Maitre74, which contain a large number of chemical structures tested.

Information on the synthesis and chemistry of the piracetam-like nootropics, plus tables of all (about 660) recorded compounds containing the 2-oxopyrrolidinacetic acid substructure (with their CA registry numbers) can be found in our parallel review on the chemistry of piracetam related nootropics100.

2. The most investigated compounds

Some 2-oxopyrrolidinacetamide nootropics have been investigated more thoroughly than others. Most of these compounds have been assigned a drug name. The named compounds are piracetam (2), oxiracetam (3), pramiracetam (4), etiracetam (5) and nefiracetam (6). Also aniracetam (7) and rolziracetam (8) have, among other compounds, been categorised as piracetam analogues (see Fig. 2).

Most previous reviews have categorised information on these nootropics according to their biochemical properties without regard for the fact that different structures are involved. Small changes in structure often lead to compounds with different chemical properties. A striking example is the poor hydrolytic stability of aniracetam and rolziracetam compared to the highly stable piracetam.
A large diversity of biochemical properties and behavioural events have been reported in the vast extant literature on nootropics and Mondadori et al.214 have stated that the dependence of their action on steroids was the first reported common property exhibited by the nootropics. With this background and the many different structures in mind we have chosen to treat each compound separately, even though this means that some repetition in the following compilations of biochemical results cannot be avoided.

This approach allows to profile each individual compound on its own merits and leads to predictions of which additional biochemical experiments, if any, would be required for further progress.

As mentioned above, no commonly accepted mechanism for the racetam nootropics has yet been established. They do not seem to act on any well characterised receptor site with the exception of nefiracetam which has high affinity for GABA, receptors (see Table 1). They can all to a certain degree pass the

Table 1
Receptor competition studies
A. Muscimol is a selective GABA, agonist, showing 417 times higher affinity for GABA, sites than for GABA, sites86.
B. Nefiracetam failed to displace 20% of the specifically bound [3H]muscimol.
C. 1-Pyroglutamate has been included in this table because of its structural similarity with the sole metabolite of rolziracetam.
D. Experiments performed in the presence of the dopamine antagonist (+)-butaclamol18.
E. The butyrophenone derivative spiroperidol possesses multiple receptor ligand activities with the following relative affinities22: D233 > 5-HT1C1 > α2(11/18) > 5-HT1A(1/40) > 5-HT2C(1/769) > α1(1/1667) = H1(1/1667) > 5-HT1B(1/3125) = 5-HT2B(1/3125)
F. Both haloperidol and spiroperidol show generally the highest affinity for dopamine D2 receptors, but the differentiation between D1 and D2 receptors is tissue-dependent131.
G. [3H]Quinuclidinyl benzilate does not, to our knowledge, distinguish between the muscarinic subreceptors.
H. Cortex.
I. Hippocampus.
J. The α1 competitive antagonist WB-4101 shows also high affinity for 5-HT1A sites (IC50 = 2 nM), but much less affinity for other 5-HT receptor subtypes (IC50 = 4-63 μM)194.
K. Clonidine, an α2-selective agonist, with additional weak H1 agonist properties17.
L. Only known to us as a β-receptor-selective ligand190.
M. Naloxone is a μ-opiate preferring antagonist, showing the following relative affinities: μ(1) > ε(1/9) > δ(1/14)192.
N. Although only referred to as an adenosine receptor ligand, it is highly selective for the adenosine-A1 receptor subtype, A1(300) = A3(1) (ref. 141). The experiments were performed in the presence of the phosphodiesterase inhibitor and weak nonselective adenosine antagonist (K, = 14 μM, displacement of [3H]cyclohexyladenosine) theophylline142.
blood–brain barrier while spanning the whole range of the lipophilicity scale, from the strongly hydrophilic piracetam to highly lipophilic compounds like aniracetam (see Table 2).

We will first examine the oldest of the racetams, i.e., piracetam, immediately followed by some of its analogues (see Fig. 3 for structures marked in bold), which do not fit readily under any of the following subheadings.

2.1. Piracetam

2.1.1. Chemical, bibliographic and historical data
Synonyms: 2-pyrrolidoneacetamide, 2-pyrrolidinoacetamide (2).
Drug codes: UCB 6215, CI-871.
Molecular formula: C₁₀H₁₆N₂O₂.
Table 2

Calculated n-octanol / water distribution coefficients (P)

A From Craig except for OPPA.
B 5-Oxo-2-pyrrolidinepropanoic acid (OPPA), the sole metabolite of roliziracetam. Calculated at pH = 7 (ref. 23).
C Nebracetam = 3-benzylaminomethyl-2-pyrolidone.
D It is not stated whether pramiracetam is ionised, but judged by its high lipophilicity it must be the unionised form.

<table>
<thead>
<tr>
<th>Compound</th>
<th>log P</th>
<th>% in n-octanol</th>
<th>% in water</th>
</tr>
</thead>
<tbody>
<tr>
<td>OPPA&lt;sup&gt;B&lt;/sup&gt;</td>
<td>-4.07</td>
<td>&lt; 0.1</td>
<td>&gt; 99.9</td>
</tr>
<tr>
<td>Piracetam</td>
<td>-1.49</td>
<td>3.1</td>
<td>96.9</td>
</tr>
<tr>
<td>Oxiracetam</td>
<td>-1.35</td>
<td>4.3</td>
<td>95.7</td>
</tr>
<tr>
<td>Etracetam</td>
<td>-0.65</td>
<td>18.3</td>
<td>81.7</td>
</tr>
<tr>
<td>Nebracetam&lt;sup&gt;C&lt;/sup&gt;</td>
<td>-0.33</td>
<td>31.9</td>
<td>68.1</td>
</tr>
<tr>
<td>Rolziracetam</td>
<td>+0.46</td>
<td>74.3</td>
<td>25.7</td>
</tr>
<tr>
<td>Aniracetam</td>
<td>+0.70</td>
<td>83.4</td>
<td>16.6</td>
</tr>
<tr>
<td>Pramiracetam&lt;sup&gt;D&lt;/sup&gt;</td>
<td>+0.76</td>
<td>85.2</td>
<td>14.8</td>
</tr>
</tbody>
</table>

Mol. wt.: 142.15 g/mol.
Martindale ID: 13124-x.
Beilstein cit.: V 21/6, p. 360.
First reported: for treatment of motion sickness in 1966 (refs. 365,367) and 1967 (ref. 99).
Discovery of effects on memory: spinal cord fixation experiments in 1968 (ref. 219) and 1971 (ref. 96), protection against hypoxia-induced amnesia in 1971 (ref. 98) and enhancement of acquisition in passive avoidance experiments with rats in 1971 (ref. 395).
Physical data (melting points): m.p. 145–147°C (from isopropanol)<sup>102</sup>, m.p. 146–149°C (from isopropanol)<sup>102</sup>, m.p. 148–150°C (from isopropanol)<sup>102</sup>, m.p. 151–152°C.

![Figure 18](image18.png)

![Figure 19](image19.png)

![Figure 20](image20.png)

![Figure 21](image21.png)

![Figure 22](image22.png)

![Figure 23](image23.png)

Fig. 3 (continued).

LD<sub>50</sub>: > 8 g/kg i.v. (rats), > 10 g/kg p.o. (rats, dogs, mice). 184

2.1.2. Clinical findings

There exist in the literature at least six reviews which summarise the clinical merits of piracetam<sup>83,94,97,236,345,378</sup>. In general, piracetam seems to be effective in patients with mild to moderate dementia (see, e.g., Hermann et al.<sup>123</sup>), while it has also been shown that piracetam can be effective in patients suffering from Alzheimer’s disease<sup>272,253</sup>, with an EEG pattern change corresponding to an increase in vigilance<sup>272</sup>. Piracetam intensifies the anticonvulsive effect of antiepileptics<sup>119,215,216,255</sup> and has been shown to be effective in parkinsonism and in the psychotic state of schizophrenics<sup>146</sup>.

Finally, treatment with piracetam has led to some improvement in dyslexia<sup>3,181</sup> (for a review, see Wilsher<sup>390</sup> and Dimond<sup>61</sup>).

Piracetam is well tolerated and without serious side effects in man (see, e.g., Coper and Herrmann<sup>49</sup>).

2.1.3. Pharmacokinetics

Piracetam is absorbed very well after p.o. administration, with a bioavailability of almost 100% and reaches peak plasma levels (about 50 μg/ml plasma, corresponding to a total concentration (bound and free) of 350 μM) 30-40 min after a 2 g p.o. dose in humans<sup>103</sup>. After a 800 mg p.o. dose to humans the peak plasma concentration is 18 μg/ml (127 μM)<sup>346</sup>. In the rat the corresponding plasma concentration...
after a 300 mg/kg orally administered dose is about 180 μg/ml (1.3 mM). Piracetam is excreted practically unchanged in the urine and completely eliminated after 30 h. The CNS half-life (7.7 h) is greater than the plasma half-life (5 h), after a 2 g p.o. dose to humans, resulting in some accumulation in the brain with time.

Piracetam crosses the blood–brain barrier slowly because of its high hydrophilicity (see Table II) and reaches peak CSF levels (about 10 μg/ml CSF, corresponding to a total concentration (bound and free) of 70 μM) 3 h after a 1 g i.v. dose.

A determination of the protein bound fraction of piracetam would be of benefit in the determination of the maximal effective dose to be administered.

2.1.4. Antiamnesic and memory-enhancing properties of piracetam

The antiamnesic and memory-enhancing properties of piracetam have been demonstrated in numerous studies with animals (see tables in refs. 83, 319, 378 or discussions in refs. 214, 230, 231, 259, 346 for a summary).

2.1.5. Interaction with γ-aminobutyric acid neurotransmission

Receptor binding studies show that piracetam has no significant effect on GABA receptors, does not affect the synaptosomal uptake of GABA (18% inhibition at 10 mM) and does not affect GABA levels in either brain or plasma.

2.1.6. Interaction with glutamate neurotransmission

Bering and Müller suggest that piracetam could accomplish some of its effects through binding to glutamate receptors, since the concentration of piracetam should be in the region of 0.1–1 mM (after 1 g i.v., man). According to Gobert, however, the peak CSF concentration in humans is rather 0.07 mM (after 1 g i.v., man), a factor of 260 less than the concentration needed (without even considering that some of the piracetam may be bound to plasma constituents) for reaching the IC50 for glutamate displacement. Bering and Müller also suggest that this may explain why so high doses must be used in order to observe an effect.

Micromolar amounts of piracetam enhance the efficacy, but not the potency of AMPA-induced calcium influx in cerebellar granule cells, an effect which persists in the presence of the voltage sensitive L-type calcium channel blocker nifedipine.

The AMPA receptor-associated ion channel is not permeable to Ca2+, but it has been shown that the AMPA and kainate receptor activation causes an increase in intracellular free Ca2+ (Ca2+_i) by calcium influx, which is partly sensitive to the L-type calcium channel blocker verapamil (40% reduction in calcium influx by verapamil channel blockade).

NMDA receptor activation increases only partly the intracellular free calcium concentration by calcium influx and causes also a co-mobilisation of calcium from intracellular stores, whereas metabotropic glutamate receptor activation causes the increase in intracellular free Ca2+ solely by intracellular calcium mobilisation.

The remaining part of the AMPA-induced calcium influx (verapamil insensitive) could be due to a co-influx through N-type (or T-type) calcium channels, supported by observations like those of Keith et al. who showed that some of the excitatory amino acid induced release of [3H]NA is caused by influx of calcium through N-type calcium channels.

The potentiated increase in AMPA-induced calcium influx caused by piracetam should therefore be a potentiation of the verapamil insensitive calcium influx and, if the increase is through N-type calcium channels, it should be blocked by ω-conotoxin. Copani et al. have also suggested an increase in the intracellular free calcium concentration by means of Na+ /Ca2+ antiport activation.

Piracetam also increases the maximal density of specific binding sites for [3H]AMPA in synaptic membranes from rat cortex. The authors suggest that this is due to recruitment of a subset of AMPA receptors which do not normally contribute to synaptic transmission.

A potentiation of ibotenate and glutamate-induced inositol monophosphate formation by chronic treatment of rats with piracetam (400 mg/kg i.p. 15 days) is observed in 16-months-old rats, but not in 2-months-old rats. No change in the number of affinity of the recognition sites for [3H]glutamate was observed, but the authors suggest that an increased coupling between glutamate receptors and phospholipase C should be responsible for the observed effects. Another possibility would be activation of phospholipase C by an increased concentration of intracellular free calcium.

Sharma and Kulkarni have shown that MK-801, an NMDA channel blocker, inhibits some of the memory improving properties of piracetam (150 mg/kg i.p., rats/mice), possibly due to inhibition of LTP induction, which seems to be involved in the memory process. The AChE inhibitor physostigmine reverses both scopolamine and MK-801 induced acquisition deficits, suggesting a cooperation between the muscarinic and the glutamatergic neurotransmission.

A potentiation of response to glutamate and aspartate through the glycine site of the NMDA receptor by piracetam has been reported in a Russian study. Another study showed that piracetam and aniracetam at 100 μM do not affect MK-801 binding in the presence of NMDA and glycine. If piracetam acts on the
glycine regulatory site of the NMDA receptor\textsuperscript{156} the presence of glycine could obscure the potentiating effect of piracetam.

It is known\textsuperscript{186} that introduction of small substituents in the \(\alpha\)-position of glycine reduces its agonist activity and that the introduction of larger substituents generates antagonists (some, however, with partial agonist activity). Piracetam, a 2-pyrrolidinone derivative, could therefore, if of any activity at the glycine modulatory site of the NMDA receptor, be expected to exhibit antagonist properties, just like the potent 2-pyrrolidinone derivative HA-966 ((\textit{R})-\textit{N}-hydroxy-3-amino-2-pyrrolidinone).

Unfortunately, in the study described above by Kaneko et al.\textsuperscript{151}, piracetam and aniracetam were not tested for their effects on AMPA and kainate responses as were other compounds. It would be reasonable to expect a potentiation of the AMPA response if piracetam somehow acts as an activator as mentioned above.

A Chinese study\textsuperscript{407} supports the involvement of the glutamatergic system in the anti-amnesic action of piracetam, since the memory improving properties of piracetam can be inhibited by ketamine, an NMDA channel blocker. Furthermore, piracetam (500 mg/kg i.p.) decreases mouse brain glutamate content and the glutamate/GABA ratio, indicating an increase in excitatory activity. Confirming this is the fact that piracetam (1–10 \(\mu\)M) potentiates \(K^+\)-induced release of glutamate from rat hippocampal slices\textsuperscript{192}.

Finally, piracetam does not inhibit the synaptosomal uptake of glutamate (24\% inhibition at 20 mM)\textsuperscript{20}.

2.1.7. Interaction with acetylcholine neurotransmission

See Pepeu and Spignoli\textsuperscript{250} for a review of piracetam-like nootropics and a cholinergic mechanism.

Piracetam ameliorates or reverses the amnesic effect\textsuperscript{42,179,271,378} (see also refs. 83 and 319 for other references) and the decrease in glucose utilisation induced by the muscarinic antagonist scopolamine. This could indicate a reestablishment of cholinergic activity.

Piracetam's effect on high-affinity choline uptake (HACU) is somewhat ambiguous. Low doses of piracetam (3–100 mg/kg i.p., rats) increase HACU activity in hippocampal synaptosomes, whereas higher doses do not (300–500 mg/kg i.p., rats)\textsuperscript{319}. Spignoli et al.\textsuperscript{335} observed a transient increase in HACU activity in rat hippocampus at 300 mg/kg i.p. and an increase in HACU has also been observed by Pedata et al. (see references in Vernon et al.\textsuperscript{378}), but other studies — (300 mg/kg i.p., rat, cortex/hippocampus)\textsuperscript{79}, (100 mg/kg chronic, rats, hippocampus)\textsuperscript{257}, (100, 500 mg/kg i.p., rat hippocampus)\textsuperscript{326} — failed to confirm this finding.

Piracetam attenuates amnesia, but potentiates ACh depletion induced by hemicholinium-3 (refs. 73,335) and Wurtman et al.\textsuperscript{399} observed a piracetam-induced decrease in the ACh content without change in the choline levels in rat hippocampus, indicating an increase in ACh release. In other studies\textsuperscript{336,337} piracetam did not change the steady state levels of ACh.

Piracetam antagonises lethality due to hemicholinium-3 (refs. 116) and neuromuscular blockade in the cat caused by \(d\)-tubocurarine\textsuperscript{226}. Pilch and Müller\textsuperscript{276} suggest that this is an effect of a stimulation of ACh synthesis by piracetam acting on HACU.

Electroconvulsive shock (ECS)-induced decrease in the ACh content in cortex and hippocampus remained unaffected by piracetam\textsuperscript{337}, but the amnesia was attenuated\textsuperscript{355}.

Chronic treatment with piracetam (500 mg/kg 1–2 weeks p.o., rats) causes an increase in the muscarinic receptor number and in the affinity for ligands. These effects were observed in both young and old rats\textsuperscript{379}. Pilch and Müller\textsuperscript{276} only observed an effect on the density of the cortical muscarinic receptors in aged rats.

A restoration of age related deficits of the central muscarinic cholinergic receptor function is also observed in mice treated with piracetam (500 mg/kg p.o., chronic)\textsuperscript{342}. According to the authors\textsuperscript{342} this is caused by a decrease in the number of receptors in the desensitised state.

Finally, piracetam did not change choline acetyl transferase (CAT) activity at 10–100 \(\mu\)M as did oxiracetam\textsuperscript{203}.

2.1.8. Interaction with noradrenaline / dopamine / 5-hydroxytryptamine neurotransmission

An increase in the firing rate of noradrenergic neurons is observed in the rat locus coeruleus after piracetam treatment\textsuperscript{245}, and increases in NA turnover in the rat brain stem have been observed after piracetam treatment\textsuperscript{265}. High doses of piracetam (600 mg/kg p.o., 5 days, rats) reverse amnesia induced by the dopamine \(\beta\)-hydroxylase inhibitor potassium ethylxanthogenate\textsuperscript{46,57}. Piracetam also increases HVA/DA\textsuperscript{257,288,300} and dopamine release\textsuperscript{398} indicating an increase in the turnover of DA, but does not affect the uptake of 5-HT\textsuperscript{286}. Very high doses of piracetam (5 g/kg i.p., over 14 days) inhibit exploratory behaviour in rats and also modify the content of NA, DA and 5-HT in different areas of the rat brain\textsuperscript{68}.

Piracetam reverses the age related decrease in biogenic amine content in old rats\textsuperscript{379}.

Piracetam (600 mg/kg daily for 30 days) causes a 20\% decrease in the activity of MAO in vivo. In vitro piracetam at 100 mM inhibited MAO\textsuperscript{200}. Another study\textsuperscript{338} observed an inhibition of MAO\textsubscript{A} and MAO\textsubscript{B} in the striatum, but a stimulation in the hypothalamus. The overall effect on MAO was stimulation. A recent Russian study\textsuperscript{31} showed that concentrations of 0.1–1
2.1.9. Interaction with steroids

Steroids are known to exert both positive and negative effects on memory\textsuperscript{206}, perhaps by influencing protein synthesis or gene expression.

Adrenalectomy, inhibition of steroid biosynthesis by aminogluthethimide and blockade of aldosterone receptors by epoxymexrenone completely suppress the memory improving effect of piracetam. This implies that aldosterone receptors might be involved in the mechanism for piracetam and since epoxymexrenone does not suppress improvements by cholinomimetics, this suggests different modes of action for the cholinomimetics and the 2-oxopyrrolidineacetamide nootropics. Neither adrenalectomy nor aminogluthethimide or epoxymexrenone treatment alone caused any significant decrease in the learning ability of the rats. Only the beneficial effects of piracetam were suppressed\textsuperscript{206,210,211}. Administration of aldosterone or corticosterone to adrenalectomised rats restores the memory-enhancing effects of piracetam-like nootropics\textsuperscript{212}, further confirming the importance of steroids in the mechanism of action of these nootropics.

High doses of aldosterone or corticosterone abolish the memory improving effects of both piracetam-like nootropics and cholinomimetics, but not the ability to learn\textsuperscript{210}. The authors therefore suggest that the high levels of steroids in Alzheimer patients may be responsible for the lack of beneficial effects of the piracetam-like nootropics.

Corticosterone and aldosterone exert negative feedback on ACTH secretion and ACTH peptide analogues have shown to improve memory in aged monkeys\textsuperscript{213}, see also Frössl and Mailt\textsuperscript{214}, Häusler et al.\textsuperscript{215} were unable to observe significant changes in the ACTH level after adrenalectomy, due to large variations of plasma ACTH concentrations.

2.1.10. Interaction with protein/lipid metabolism

Cycloheximide, a protein synthesis inhibitor, induces amnesia which is ameliorated by piracetam\textsuperscript{53} and piracetam enhances both phospholipid and protein synthesis\textsuperscript{210,211,212} (see Davis and Squire\textsuperscript{56} for a review on protein synthesis and memory).

The membrane fluidity decrease with age or induced by scopolamine is reversed by piracetam and this has been suggested to be caused by its normalising effects on the lipid content of the synaptosomes\textsuperscript{209,213} (see also Müller\textsuperscript{221}).

Piracetam exerts a non-specific stabilising effect on lipid membranes in stress situations where an increase in lipid peroxidation is seen. This effect could not be directly related to specific enzymes\textsuperscript{212}.

Inhibition of the T-cell component of the immune system is accompanied by an increase in lipid peroxidation. Piracetam favours the normalisation of immunity by affecting lipid peroxidation\textsuperscript{187}.

2.1.11. Other effects

Piracetam activates brain adenylate kinase\textsuperscript{233} and produces a significant increase in the cerebral glucose utilisation in the whole brain of rats\textsuperscript{112}. Also in man, an increase in glucose utilisation was observed\textsuperscript{221}; furthermore it has been observed that piracetam (1 g/kg) enhances the compensatory capacity of mito-

Xoaretetam, piracetam, nefiracetam and etiracetam may, of course, all be considered as close ana-
logues of piracetam as may their derivatives, but since these compounds have been the subject of much interest they are treated separately.

Under this subheading we will treat compounds chemically related to piracetam which cannot be regarded as close analogues of the above-mentioned special derivatives.

2.2.1. Substituted 2-oxopropylideneacetamides

Piracetam and a number of N-substituted 2-oxopropylideneacetamide derivatives were originally prepared as agents for the treatment of motion sickness and as antiemetics. N-Phenyl substitution of piracetam, which may be considered as a close analogue of neferacetam, leads to a compound with psychotropic and depressant activity. 4-Phenyl substitution of piracetam leads to a compound with psychostimulatory activity at low doses and behaviour inhibitor activity at high doses. The N-adamantyl derivative of 4-phenylpiracetam is inactive. Other N-substituted 4-phenyl analogues of piracetam have been tested for effects on GABA uptake, but were all of low intrinsic activity and potency.

Different compounds (9) connected through the acetamide group have been prepared. Of these dupracetam (Z = NHNH) has proved to antagonise the lethal effect of hemicholinium-3 (30 mg/kg i.p., mice) in mice.

The kinetics of dupracetam hydrolysis has been determined. In neutral media dupracetam is resistant to 30 h of heating, whereas it hydrolyses to 2-oxopropylideneacetic acid hydrazide and 2-oxopropylideneacetic acid upon 1.5 h boiling in acidic media. Dupracetam is thus stable to uncatalysed hydrolysis, but whether dupracetam is subject to reduction by reductases in vivo, which would generate piracetam, is unknown.

Other substituted 2-oxopropylideneacetamides have been prepared and tested for nootropic activity. The 3-pyrroline analogue of piracetam as well as other pyrrolidine derivatives have been prepared.

2.2.2. 2-Oxopropylideneacetic acid, its hydrazide and ester derivatives

α-Phenoxyl-2-oxopropylideneacetic acid has been tested for analgesic activity. Hydrazides and esters of piracetam nootropics have been prepared and screened for nootropic activity. It seems that psychotropic and stimulant activities are associated with the hydrazides as in the case of piracetam.

drazides and esters have been prepared and tested (172,173,174,294) (see also Gouliaev et al. 106).

2.2.3. Amidines and amidoximes of piracetam

Amidine (340,384) and amidoxime (102) analogues (10) of piracetam, some of which show nootropic activity similar to piracetam, have been prepared.

2.2.4. 2-oxopyrrolidine derivatives

The 3-pyrrole analogue (11) of piracetam as well as other pyrrolidine derivatives have been prepared (275).

Benzol d'piracetam has been synthesised, but no data concerning nootropic activity are available from Valenta et al. (258).

2.2.5. Thiocarbonyl analogues

A number of thiocarbonyl analogues (12) of piracetam derivatives have been prepared (109,110,111,114,147,148,165). The thiocarbonyl analogues all show antihypoxic, anti-convulsant and psychotropic effects at lower doses than piracetam, perhaps because of better diffusion across the blood-brain barrier. Biotransformation studies have been carried out. The dithiocarbonyl analogue of piracetam yields piracetam on biotransformation or undergoes intramolecular cyclodehydration, elimination of H₂S and reductive loss of sulfur which finally leads to 5,6-dihydro-7H-pyrrolo[1,2-z]imidazole. Elimination of H₂S, yielding the corresponding nitrile, has also been observed. None of the metabolites surpass the antihypoxic activity of the parent compound.

2.2.6. Cyclo- and side chain-modified homologues

Ring or side-chain-expanded analogues of 2-oxopropylideneacetamides have been prepared (15,131,277,291,294,295) (13).

It seems that the 5-membered ring is crucial for the psychotropic effects although the 6-membered ring compounds also show some effect.

2.2.7. Tacrine analogues

A considerable number of close analogues containing substituents in the amide group of piracetam, which may be related to the AChE inhibitor tacrine, have been prepared (14). An increase in the activity of HACU at concentrations of 10 nM and an improvement in brain function (13%) at 100 nM in rats have been reported. According to two Russian studies, the anti-amnesic effect of tacrine and amiridine (an analogue) is not due to their effects on AChE, since they show anti-amnesic effects at 0.1 mg/kg, a concentration in which they do not affect AChE.

2.2.8. Peptide analogues

Peptide-like compounds (15) have been shown to be
Some of the different peptide analogues of piracetam such as, e.g., N-carbamoylmethylprolinamide have been prepared in order to test the possibility of the existence in the brain of receptors for piracetam-like nootropics. SAR investigations support this hypothesis and suggest that the endogenous ligands should resemble pyroglutamate (agonist) or proline (antagonist). Furthermore the \( \alpha \)-form of pyroglutamylglycineamide causes amnesia while the \( \beta \)-form has antiamnesic properties\(^{1,14}\). Pyroglutamate itself, however, is known to be antiamnesic whereas \( \beta \)-proline has amnesic properties\(^{1,14,270,334}\).

### 2.2.9. Prolylleucylglycine analogues

Prolylleucylglycine (PLG) analogue, has been prepared as part of structure–activity study and shown to enhance \( [3H]ADTN \) (2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene, a dopamine agonist) binding to membranes and/or modulate dopamine receptor supersensitivity\(^{145,201,370,406}\). Furthermore, this compound inhibits the GTP-induced conversion of the dopamine D\(_2\) receptor from its high affinity to a low-affinity state\(^{201}\). The dopamine D\(_2\), but not the D\(_1\) receptors, in the caudate nucleus seem to play a specialised role in the memory process\(^{137}\).

### 2.2.10. Thyrotropin-releasing hormone analogues and prolylendopeptidase inhibitors

Thyrotropin-releasing hormone (TRH) is known to improve memory and scopolamine-induced deficits in volunteers\(^{27,205}\). TRH and other neuropeptides like, e.g., vasopressin are degraded by prolylendopeptidase (PEP) and inhibitors of PEP should therefore possess antiamnesic properties.

Pramiracetam, aniracetam and piracetam inhibit PEP\(^{50,403}\). They have, together with other analogues of piracetam, been subjected to a QSAR study\(^{50}\).

### 2.2.11. Renin inhibitors

Compounds containing the 2-oxopyrrolidineacetamide acid or amide moiety, but not necessarily close analogues of piracetam, have been tested as renin inhibitors\(^{57,242,350,351,359}\).

### 2.2.12. Angiotensin-converting enzyme inhibitors

Different compounds containing the 2-oxopyrrolidineacetamide acid moiety have been investigated as angiotensin-converting enzyme (ACE) inhibitors\(^{153,323,352–354}\). Inhibition of ACE appears to cause improvements of cognitive performance (for a review, see Pavia et al.\(^{255}\)), although this could be due to some of the structural similarities between the ACE inhibitors and the piracetam-like nootropics and may therefore not be due to inhibition of ACE nor that of renin, but the possibility can, of course, not be ruled out.

### 2.2.13. Other analogues of piracetam

In this section we will treat the remaining 2-oxopyrrolidineacetamide compounds which have been tested for nootropic activity. Compounds which have been prepared, but not subjected to screening tests, will not be cited.

Compound (16) improves passive avoidance by 39% at 100 mg/kg p.o. in rats\(^{238}\). Analogues of (16) have also been prepared. This compound is a rather complex drug because it is a combination of piracetam, glycine (which may play some role in the early phase of memory processing after a passive avoidance task\(^{209}\)) and 4-aminopyridine which is known as a non-selective potassium channel blocker\(^{361}\). Blocking of the potassium channels with 4-aminopyridine has been shown to cause increased release of ACh through delay of repolarisation\(^{320}\). 3,4-Diaminopyridine (0.1 mg/kg i.p., rats) affects sodium-dependent choline uptake, but 4-aminopyridine (0.01–3.0 mg/kg i.p., rats) does not\(^{320}\). For a blockade of potassium channels to occur 4-aminopyridine must be released by hydrolysis of the amide bond in (16).

Analogues of CGP25248, cebracetam (17) have been prepared and shown to possess a high activity in the Mondadori–Waser passive avoidance test at 3 mg/kg i.p.\(^{43}\). Opening of the pyrrolidinone ring gives a compound containing the 4-amino-3-(4-chlorophenyl)butyric acid moiety. (\(R\))-4-Amino-3-(4-chlorophenyl)butyric acid, also known as (\(R\))-baclofen, is a GABA\(_B\) agonist, whereas the (\(S\))-form is inactive\(^{162}\). GABA\(_B\) receptors are probably involved in the release of other neurotransmitters\(^{160}\) and regulate induction of LTP\(^{55}\).

Finally, (18) has been shown to be effective as an anticonvulsant and antihypoxic agent at doses lower than those necessary with piracetam and its thiacarbonyl analogues\(^{87}\).

### 2.3. Oxiracetam

#### 2.3.1. Chemical, bibliographic and historical data

**Synonyms:** 4 hydroxy 2 oxo-1 pyrrolidineacetamide, hydroxypiracetam (3).

**Drug codes:** (±)-form: CT-848, ISF 2522.


**Molecular formula:** \( C_8H_{10}N_2O_3 \).

**Mol. wt.:** 158.16 g/mol.

**Martindale ID:** 16922-v.

**Beilstein cit.:** V 21/12, p. 19.

Preparation: refs. 15, 273 and 274
Spectroscopic data: ref. 273
Physical data (melting points): (R)-form: m.p. 135–136°C (from acetone/water), [α]D = +36.2° (c = 1, water); (S)-form: m.p. 135–136°C (from acetone/water), [α]D = −36.2° (c = 1, water); (+)-form: m.p.

Table 3
Effect of oxiracetam on various types of chemically/physically induced amnesia, lethality and recovery after insult

<table>
<thead>
<tr>
<th>Treatment in mg/kg*</th>
<th>Measure</th>
<th>Species</th>
<th>[oxiracetam] in mg/kg*</th>
<th>Effect</th>
<th>Refs.</th>
</tr>
</thead>
<tbody>
<tr>
<td>None:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maze</td>
<td>Rats</td>
<td>30, 100 i.p.</td>
<td>NS</td>
<td>189</td>
<td></td>
</tr>
<tr>
<td>Learning</td>
<td>Rats</td>
<td>10 i.p.</td>
<td>I</td>
<td>164</td>
<td></td>
</tr>
<tr>
<td>Learning</td>
<td>Rats</td>
<td>10–60 i.p./p.o.</td>
<td>I</td>
<td>14</td>
<td></td>
</tr>
<tr>
<td>Learning</td>
<td>Mice</td>
<td>1</td>
<td>I</td>
<td>271</td>
<td></td>
</tr>
<tr>
<td>Active</td>
<td>Mice</td>
<td>25, 50 i.p.</td>
<td>I</td>
<td>312</td>
<td></td>
</tr>
<tr>
<td>Active</td>
<td>Mice</td>
<td>50</td>
<td>I</td>
<td>310</td>
<td></td>
</tr>
<tr>
<td>Passive</td>
<td>Mice</td>
<td>50</td>
<td>NS</td>
<td>310</td>
<td></td>
</tr>
<tr>
<td>Passive</td>
<td>Mice</td>
<td>16–475 i.p.</td>
<td>NS</td>
<td>376</td>
<td></td>
</tr>
</tbody>
</table>

Modulation of Glu neurotransmission:

AP-5
6 mg/2 ml i.c.v.*
Passive Rats 50–500 s.c.* RE 250

Modulation of ACh neurotransmission:

Scopolamine
3 i.p.*
0.63–0.66 s.c.*
0.6 s.c.*
0.2 s.c.*
Nicotine
1 i.p.*
Mecamylamine
2.5, 5 i.p.
Hemicholinium-3
149 i.p.* (= LD50)
15 μg i.c.v.

Blockade of Ca2+ channels:

Diltiazem
10^A

ECS:

Passive Rats 10^B AA 38
Passive Rats RE 229
Passive Rats 100, 300 i.p. AA 337
Learning Rats 50, 100 i.p. AA 201

Hypoxia:

Recovery Rats 100 i.v. I 155
2.3.2. Clinical findings

Oxiracetam has been investigated for potential use in different forms of dementia and is reported to be well tolerated and without any side effects\(^{134,204,252,303,374,380,381}\).

The use of oxiracetam in patients suffering from Alzheimer's dementia (800 mg p.o. b.i.d. for 3 months), epilepsy (800 mg p.o. t.i.d.) or long-term exposure to organic solvents (1.2 g p.o. b.i.d. for 3 months) has not met with convincing success\(^{4,6,7,12,26,47}\). Also in elderly patients suffering from exogenic post-concussion syndromes\(^{64,303}\) has there been an improvement after treatment with oxiracetam. Oxiracetam seems more effective than the prototype nootropic piracetam\(^{8}\) (for a review on clinical results see Maina et al.\(^{191}\)).

On the other hand, many studies report beneficial effects on logical performance, attention/concentration, memory and orientation after chronic use of oxiracetam (800–2400 mg p.o. once or twice a day for 1–6 months) in dementia of mild to moderate degree\(^{17,154,191,204,252,381}\). Also in elderly patients, patients suffering from exogenic post-concussion syndromes\(^{64,303}\) has there been an improvement after treatment with oxiracetam. Oxiracetam seems more effective than the prototype nootropic piracetam\(^{8}\) (for a review on clinical results see Maina et al.\(^{191}\)).

2.3.3. Pharmacokinetics

Methods for determining oxiracetam in plasma and urine have been developed\(^{178,347}\). It has been shown that oxiracetam is well absorbed from the GI after p.o. administration, with a bioavailability of 68–82%\(^{263,56}\) and mainly excreted by renal clearance\(^{111,371,374}\). As much as 84% is recovered as unchanged oxiracetam in the urine after a single 800 mg p.o. dose. The peak level of oxiracetam is reached within 1–3 h after a single 800 mg p.o. or 2000 mg p.o. dose, with a serum concentration of 19–31 μg/ml (corresponding to a total concentration (bound and free) of 120–196 μM)\(^{284}\) and 40 μg/ml (250 μM)\(^{283}\), respectively. The terminal plasma half-life after a 800 mg p.o. dose in healthy people is about 8 h, whereas patients suffering from renal impairment may exhibit long half-lives of 10–68 h\(^{176,177}\). Oxiracetam does, to some extent, penetrate the BBB\(^{113,251}\) and a concentration of 2.8 μg/ml a total concentration (bound and free) of 18 μM, corresponding to 5.3% of the serum concentration, is reached 1 h after a single 2 g i.v. dose\(^{251}\). This contradicts a study by Mondadori and Petschke\(^{213}\) who could not observe any significant amounts of tritium in the rat brain by autoradiography after a 10 ms/kg i.v. dose of \(^{3}H\)oxiracetam.

The plasma steady-state concentration of oxiracetam, after administration of 800 mg b.i.d. to persons with a creatine clearance ranging from 9 to 95 ml/min, has been estimated to range from 530 μM to 60 μM (total concentration: bound and free)\(^{177}\).

Oxiracetam is found with the highest concentrations in the septum, followed by the hippocampus, the cerebral cortex and with the lowest concentration in the striatum after a 200 mg/kg p.o. administration to rats. A similar distribution pattern is observed after i.c.v. administration\(^{280,347}\).

2.3.4. Antiamnesic and memory-enhancing properties of oxiracetam

Table 3 summarises selected antiamnesic and memory-enhancing properties of oxiracetam (see the text for discussion).

2.3.5. Interaction with glutamate neurotransmission

Treatment of rats with AP-5, an NMDA antagonist, prior to training impairs passive avoidance performance. This can be prevented by pretreatment with oxiracetam or D-pyroglutamic acid\(^{250}\). Oxiracetam (0.1–100 μM) provokes a concentration-dependent (maximum effect at 1 μM) prolonged increase in neurotransmission in the CA1 rat hippocampal region and application of AP-5 (50 μM), which prevents induction of LTP, blocks this effect of oxiracetam\(^{287}\). The effect of oxiracetam is dose-dependent, and oxiracetam in high concentrations (100 μM–1 mM) actually inhibits pyramidal neuronal excitability, diminishing the EPSP and causing a slight hyperpolarisation\(^{244}\). These results imply that NMDA receptors might be involved in the action of oxiracetam either directly or indirectly, but since it is also known that oxiracetam (10 nM–1 μM) increases the release of glutamate from depolarised rat hippocampal slices, but not the spontaneous release\(^{152}\), this finding could support an indirect mechanism. Further support of oxiracetam's stimulating actions on the glutamate receptor system stems from the result that pretreatment of rats with oxiracetam reverses the AP-7 (an NMDA antagonist)-induced increase in ACh content\(^{279}\). AP-7 is known to inhibit NMDA stimulated ACh release in vitro\(^{330}\).

Micromolar amounts of oxiracetam enhance the efficacy, but not the potency of AMPA-induced calcium influx in cerebellar granule cells, an effect which persists in the presence of the voltage sensitive L-type\(^{359}\) calcium channel blocker nifedipine. The effect exerted by oxiracetam was specific for signal transductions mediated by the AMPA sensitive glutamate receptor. Only AMPA, but not NMDA nor kainate-induced calcium influx was augmented (see also discussion in subsection 2.1.6). Furthermore, oxiracetam did not affect phosphoinositol turnover, indicating that it does not act on the metabotropic glutamate receptor\(^{48}\).

Copani et al.\(^{48}\) suggest that the oxiracetam-induced release of glutamate, is secondary to the selective potentiation of the AMPA response. The induced release
of glutamate could then be a result of retrograde messenger stimulation, for which arachidonic acid, nitric oxide or carbon monoxide seem to be likely candidates.

Oxiracetam, like piracetam, increases the maximal density of specific binding sites for $[^{3}H]$AMPA in synaptic membranes from rat cortex.

This may also support the hypothesis that the effect on NMDA receptors is indirect. Much seems to indicate a role of LTP in memory mechanisms and it is known that glutamate cannot induce LTP through NMDA receptors without concomitant activation of the acceptor cells via other receptors, among which the AMPA receptors seem to be good candidates.

Potentiation of the AMPA response would thus ease the induction of LTP.

2.3.6 Interaction with acetylcholine neurotransmission

Oxiracetam stimulates choline uptake into isolated hippocampal slices from spontaneously hypertensive rats with sodium chloride induced cerebrovascular lesions, which without oxiracetam display a decrease in both choline uptake and incorporation of choline in lipids. Chronic treatment with oxiracetam (100 mg/kg i.p., rats) increases HACU activity with concomitant increase in ACh utilisation and without affecting the steady-state ACh level.

Reduction in ACh content and HACU activity can be achieved by physical interruption of corticostriatal pathways. The muscarinic agonist oxotremorine (0.8 mg/kg i.p., rats) and the dopaminergic agonist apomorphine (1 mg/kg i.p., rats), which normally increase the ACh content, could not restore HACU activity nor the ACh content. On the other hand, oxiracetam (100 mg/kg i.p., rats) restores HACU activity and also the normal activity of oxotremorine and apomorphine. The authors suggest that this should be due to an increase in choline availability.

In frontal cortically deafferented rats a decrease in the number of $[^{3}H]$hemicholinium binding sites, but no change in affinity is observed. This decrease in the number of binding sites is reversed by oxiracetam, leaving the affinity unchanged. Finally the lethal effect of hemicholinium-3 (30 mg/kg i.p., mice) is antagonised by oxiracetam (30–300 mg/kg i.p., mice).

Oxiracetam ameliorates/antagonises amnesia and the ACh depletion induced by ECS or scopolamine in the hippocampus and the frontal cortex in a bell-shaped dose-response manner. The rather high subcutaneous dose of 300 mg/kg oxiracetam administered to rats is ineffective.

A direct injection into the lateral ventricles of the rat of 2–20 nmol oxiracetam, which corresponds to the estimated amount reaching the brain after 200 mg/kg p.o. or 100 mg/kg i.a. administration, reverses scopolamine (0.66 mg/kg s.c.)-induced amnesia. The peripherally acting muscarinic antagonist methylscopolamine (0.2 mg/kg s.c., rat) does not decrease performance as observed with scopolamine (0.2 mg/kg s.c., rat), indicating centrally mediated effects of scopolamine on memory. Peripheral effects of methylscopolamine (0.63 mg/kg s.c., rat) can on the other hand also be induced by scopolamine (0.63 mg/kg s.c., rat). These effects remain unperturbed by oxiracetam.

The effects of a rather high concentration of scopolamine (3 mg/kg i.p., mice) could not be reversed by oxiracetam as they were by piracetam and etiracetam. Lower doses of oxiracetam than of piracetam are normally sufficient to attenuate or reverse amnesia and observations like these could therefore indicate differential modes of action.

Oxiracetam potentiates the memory improvement, in mice, by secovarine, a presynaptic muscarinic blocker and combining the two in concentrations which by themselves are inactive results in a significant improvement of the performance in a passive avoidance task.

Oxiracetam (50 mg/kg, i.p., rats) also acts synergically with nicotine (0.5 mg/kg, i.p.) and reverses the inhibitory effect of higher concentrations of nicotine (1 mg/kg, i.p.) in an active avoidance test. It therefore seems reasonable to suppose that oxiracetam's main mechanism does not involve nicotinic receptor activation.

Mecamylamine (2.5–5 mg/kg i.p., mice), a nicotinic antagonist with preference for CNS located receptors, suppresses both passive and active avoidance learning in mice. Oxiracetam (50–100 mg/kg i.p., mice) prevents suppression of active avoidance learning, but not of passive avoidance. The authors suggest that the prevention of mecamylamine-induced suppression of active avoidance performance may indicate that central nicotinic mechanisms are involved in the improvement seen with this nootropic drug. The previously mentioned results by Sansone et al., however, only indicate an indirect action of oxiracetam on nicotinic receptor response.

Oxiracetam (10–100 μM) enhances K+−induced ACh release from rat hippocampal slices and stimulates CAT, but does not affect the concentration curve for the displacement of $[^{3}H]$QNB by the muscarinic agonist carbachol. Moreover oxiracetam alone does not affect $[^{3}H]$QNB binding in cerebral cortex and hippocampus and changes neither $K_{d}$ nor $B_{max}$ for $[^{3}H]$QNB binding after repeated treatment (100 or 500 mg/kg p.o.) of old rats. Finally, oxiracetam did not affect AChE activity in mouse brain homogenate. The authors suggest an enhancement of the presynaptic cholinergic function.

A selective decrease in central noradrenergic and dopaminergic, but not 5-HT, pathways abolishes the beneficial effect of oxiracetam on scopolamine-induced amnesia and decreased ACh levels.
2.3.7. Interaction with noradrenaline / dopamine neurotransmission

Oxiracetam (50 mg/kg i.p., 7 days, mice) acts synergistically with methamphetamine to effect an improvement of active avoidance without influencing the locomotor effects of methamphetamine. Oxiracetam alone gave no significant improvement. This could imply that for the improvement by oxiracetam to be possible some 'pre-alertness' must be present in this type of test106.

Treatment with oxiracetam (100 mg/kg, s.c., 5 days, rats) does not change the levels of DA and of the metabolite HVA357.

2.3.8. Interaction with calcium channels

Blockade of L-type calcium channels by dihydropyridines causes a reduction in memory retention when given prior to training, but not if administered after. Furthermore, a two-fold reduction in the density of L-type559 calcium channels is observed in rat cerebral cortex after treatment with the calcium channel blocker diltiazem. These effects can be completely reversed by oxiracetam administered immediately after training or prevented by pretreatment or chronic treatment25,63.

2.3.9. Interaction with steroids

Adrenalectomy, inhibition of steroid biosynthesis by aminogluthethimide and blockade of aldosterone receptors by epoxymexrenone completely suppress the memory improving effect of oxiracetam (see previous discussion in subsection 2.1.9).

2.3.10. Interaction with protein / lipid metabolism

A change in lipid composition might be important in excitable membranes261 and it has been observed that oxiracetam reverses the decrease in phospholipids, especially in the hippocampus and the cortex, observed in spontaneously hypertensive rats with cerebrovascular lesions261,362. Another explanation would be that the increase in phosphatidylcholine synthesis is only seen after some time indicating that oxiracetam acts on the turnover of phospholipids rather than on their rate of synthesis362. Another explanation would be that the increase in phosphatidylcholine synthesis may be secondary to an increased choline uptake228.

Oxiracetam (100 mg/kg, i.p.) stimulates protein kinase C in rats. Higher concentrations of oxiracetam inhibit PKC (ref. 107). This stimulatory effect on PKC could, however, be a secondary effect due to an increase in the intracellular free calcium ion concentration.

A number of GABOB analogues (19) have been investigated for effects on protein synthesis and phospholipid synthesis in brain slices from rats pretreated with the compound to be tested258.

Of these, only oxiracetam and 4-acetox-2-oxopyrrolidine-1-acetamide were able to increase phospholipid synthesis significantly. Some of the other compounds even inhibited phospholipid synthesis.

The 4-acetylxyethyl esters enhanced protein synthesis as did the 4-hydroxyamides. The rest did not significantly promote protein synthesis, some derivatives inhibited it.

Only oxiracetam enhanced both protein and phospholipid synthesis.

2.3.11. Other effects

No effect on locomotor activity has been observed after treatment (25–50 mg/kg i.p., mice) with oxiracetam312.

Prenatal treatment of mice with oxiracetam makes them more interactive with their environment and they perform better in a maze test. These results suggest an enhanced cognitive development upon prenatal oxiracetam treatment. No effects on weight, sensory motor reflexes and motility were observed128. Treatment of pregnant rats with methylazoxymethanol, an antimitotic compound, prevented the development of neurons in the cortex and hippocampus of the offspring. Oxiracetam reverses this effect12.

Pretreatment with oxiracetam (400–800 mg/kg i.p.) ameliorates the decrease in glucose utilisation induced by occlusion of the left middle cerebral artery in rats128.

Pretreatment with oxiracetam also antagonises the reduction, induced by either low glucose or low oxygen supply, in the amplitude of evoked potentials (rat cerebral cortical slices) in a dose dependent manner (10–5–10–6 M)129.

2.4. Analogues of oxiracetam

2.4.1. 4-Alkoxy-/ 4-acyloxy-2-oxopyrrolidineacetic acid derivatives

Different analogues of 4-hydroxy-2-pyrrolidinone, 4-alkoxy-2-pyrrolidinone and 4-acyloxy-2-pyrrolidinone derived nootropics (20) have been subjected to nootropic tests11.

All these compounds were without acute toxicity at the highest tested dose of 1 g/kg i.p. in rats. It was shown that alkylation and acetylation of the hydroxy-group as well as side chain elongation reduced the beneficial effect in passive avoidance and pole climbing tests. Changing the amide to an acid or ester group also led to a lesser beneficial effect in the pole climbing test (perhaps because of easy hydrolysis of the ester and difficulty for the acid to pass the BBB). Of the compounds tested those containing R1 = H, CH3COOH, CH2CH2CONH2 were not significantly better than saline in passive avoidance (100 mg/kg i.p.). Changing the N-acetamide to an N-acetyl group gives a compound with about the same efficiency in the passive avoidance, but less in the pole climbing test.
There were no differences in the beneficial effects of (R), (S) or (±)oxiracetam. This would appear strange if oxiracetam should act as the ring opened compound on GABA receptors, since (R)-GABOB is known to inhibit GABA_B binding and (S)-GABOB to be inactive.

2.4.2. 3-Hydroxy-analogues of oxiracetam

N-Substituted 3-hydroxy, 3,4-dihydroxy, O-alkyl and O-acyl derivatives of 2-oxopyrrolidineacetamide have been prepared and shown to be effective in improving performance in passive avoidance at 0.01–50 mg/kg p.o. in rats.

2.5. Pramiracetam

Pramiracetam stands out from the other pyrrolidoneacetamide nootropics, which chemically seen are neutral compounds, by being a basic compound.

2.5.1. Chemical, bibliographic and historical data


CAS RN (number of refs. 1967–Dec. 26, 1992): [68497-62-1] (34 refs.), sulfate: [72869-16-0] (3 refs.). Molecular formula: C_{14}H_{27}N_{3}O_{2}.

Mol. wt.: 269.39 g/mol.

Martindale ID: 16967-a.

Beilstein cit.: ONLINE DIALOG BASE 390, Record No. 1539543.

First reported/first reported as nootropic: 1978 (ref. 183).

Preparation: refs. 183 and 185.

Physical data (melting and boiling points): m.p. 47–48°C (monohydrate)\(^{185}\), b.p. 164°C \(^{183}\) (3 refs.).

LD\(_{50}\): sulfate: 5.434 g/kg p.o. (male mice), 4.355 g/kg p.o. (female mice)\(^{186}\).

2.5.2. Clinical findings

As is the case for most of the 2-oxopyrrolidine-1-acetamide nootropics, pramiracetam is well tolerated and without side effects\(^{185}\). Pramiracetam, 400 mg t.i.d. for 10 months, was given as a treatment of males with sustained brain injuries. An improvement was observed which was also present one month after ended treatment\(^{185}\). Doses up to 4 g daily were without benefit to patients suffering from Alzheimer’s disease in one study\(^{184}\), but showed encouraging activity in another\(^{33}\).

2.5.3. Pharmacokinetics

Oral absorption of pramiracetam is moderately rapid, peak plasma concentrations (2.7–9.0 g/mL) corresponding to a total concentration (bound and free) of 10.0–33.4 g/mL being reached 2–3 h after a 400–1600 mg p.o. dose given to healthy volunteers\(^{29,40}\). The harmonic mean elimination half-life (4.5–6.5 h), the total body clearance (4.45–4.85 mL/min/kg), the mean renal clearance (1.8–3.0 mL/kg/min) and the mean apparent volume of distribution (1.8–2.9 L/kg) have been shown to be independent of dose\(^{40}\). Chang et al.\(^{40}\) suggest that the clearance values are relatively small compared to the hepatic blood flow, suggesting that little or no first-pass metabolism will occur, provided that the drug is not metabolised in the gut. Unidentified metabolites, together with unchanged pramiracetam which is mainly excreted through the urine, have, however, previously been observed by Young and Chang in rats and monkeys\(^{405}\).

2.5.4. Antiamnesic and memory-enhancing properties of pramiracetam

Table 4 summarises selected antiamnesic and memory-enhancing properties of pramiracetam. See the text for discussion.

2.5.5. Interaction with \(\gamma\)-aminobutyric acid neurotransmission

Pramiracetam does not affect GABA uptake (10% inhibition at 50 \(\mu\)M)\(^{286}\).

2.5.6. Interaction with acetylcholine neurotransmission

Pramiracetam reverses scopolamine effects on choline transport across the BBB, which might be regulated by cholinergic innervation of brain endothelial cells according to Brust\(^{28}\).

Pramiracetam increases HACU in hippocampus, cortex and striatum in a dose responsive manner\(^{79,257,289,326}\), but the effect disappears 24 h after

---

Table 4

<table>
<thead>
<tr>
<th>Treatment Measure</th>
<th>Species</th>
<th>(Pramiracetam) Effect Ref. in mg/kg*</th>
<th>(Pramiracetam) Effect Ref. in mg/kg*</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>Learning Rats 30 i.p.(^{A})</td>
<td>1</td>
<td>65</td>
</tr>
<tr>
<td></td>
<td>Maze Rats 7.5–15 i.p.(^{D})</td>
<td>1</td>
<td>220</td>
</tr>
<tr>
<td></td>
<td>Learning Monkeys 0.5 p.o.(^{D})</td>
<td>1</td>
<td>286</td>
</tr>
<tr>
<td></td>
<td>Learning Rats 1.25 p.o.(^{A})</td>
<td>1</td>
<td>286</td>
</tr>
<tr>
<td>Modulation of ACh neurotransmission:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HC(_{3})</td>
<td>113 i.p.(^{A}) (= LD(_{50})) Lethality Mice 100 i.p.(^{A})</td>
<td>RE</td>
<td>116</td>
</tr>
<tr>
<td></td>
<td>1.5 (\mu)g i.c.v.(^{A}) Passive Mice 100 i.p.(^{A})</td>
<td>RE</td>
<td>73</td>
</tr>
<tr>
<td>ECS:</td>
<td>Active Mice 1.25–80 i.p.(^{B})</td>
<td>RE</td>
<td>33</td>
</tr>
<tr>
<td></td>
<td>Learning Rats 5–160 p.o.(^{A})</td>
<td>AA</td>
<td>286</td>
</tr>
</tbody>
</table>
administration\textsuperscript{79}. Pramiracetam reverses hemicholinium-3-induced amnesia\textsuperscript{79}.

Pramiracetam improves avoidance learning as do physostigmine and oxotremorine, as learning to the peripherally acting AChE inhibitor neostigmine and the peripheral muscarinic antagonist methylatropine\textsuperscript{108}.

2.5.7. **Interaction with noradrenaline / dopamine / 5-hydroxytryptamine neurotransmission**

Pramiracetam (100 mg/kg i.p., rats) does not change the concentration of NA\textsuperscript{209} nor the concentration or turnover of 5-HT\textsuperscript{289} and DA in striatum and hippocampus\textsuperscript{267,289}. Furthermore, pramiracetam does not affect 5-HT uptake (12% inhibition at 50 \mu M)\textsuperscript{286}.

2.5.8. **Interaction with steroids**

Adrenalectomy, inhibition of steroid biosynthesis by aminoglutethimide and blockade of aldosterone receptors by epoxymethrene completely suppress the memory improving effect of pramiracetam (see previous discussion in subsection 2.1.9).

2.5.9. **Other effects**

Pramiracetam inhibits (K$_i$ = 11 \mu M) the enzyme prolylendopeptidase (PEP) in some brain areas, but not in others. Inhibition was observed with the highest effect in the mesencephalon, followed by the striatum, cerebellum, hippocampus and hypothalamus, but no inhibition was observed in the cerebral cortex and the medulla oblongata\textsuperscript{50,403}.

Pramiracetam normalises the EEG pattern of aged rats to resemble that observed in young rats in a bell-shaped dose responsive manner\textsuperscript{285,284}.

Pramiracetam have also been shown to increase cerebral blood flow\textsuperscript{28}.

2.6. **Analogues of pramiracetam**

N-Substitution of piracetam leads, in general, to more active compounds\textsuperscript{33,184}. N-(Aminooethyl)-2-oxopyrrolidine-1-acetamide derivatives\textsuperscript{36,109} (21) and N(1-piperazidinyl)-2-oxopyrrolidine-1-acetamide derivatives\textsuperscript{369,402} (22) inhibit the amnesia induced by the protein synthesis inhibitor cycloheximide as well as ECS-induced amnesia. In the ECS-induced amnesia test, compounds containing \( \gamma \)-(N,N-dioisopropylami-no)ethyl-(pramiracetam) or 2-(2,6-dimethylpiperidin-1-yl)ethyl-enethiones were most efficient. The (CH$_2$)$_2$ side chain length, the acetamido moiety and the pyrrolidone ring were important for activity. Compounds containing a (CH$_2$)$_4$ side chain, the acetamido moiety or a piperidone ring either had lower intrinsic activity, were less potent or had a smaller activity range\textsuperscript{33}. N-(2-Hydroxyethyl)piracetam and N-(2-alkoxyethyl)piracetam (21) which may be considered as nonbasic analogues of pramiracetam, are equipotent with piracetam\textsuperscript{89}.

Structurally related is (23). It exhibits brain function activating activity at 1–10 mg/kg p.o. and protective activity at 0.1–10 mg/kg p.o. in rats and mice\textsuperscript{167,168}.

Amides of acetylcholine are known to be inactive as cholinergic agonists\textsuperscript{38,8} and pramiracetam has no significant affinity for muscarinic receptors. 2-Oxopyrroolidine-1-acetic acid 2-(N,N-dimethylamino)ethyl ester (24), which may be considered as a combined analogue of pramiracetam and ACh, does, however, significantly improve the performance of rats (40 mg/kg s.c.) in passive avoidance\textsuperscript{366}.

2.7. **Etiracetam**

2.7.1. **Chemical, bibliographic and historical data**

Synonyms: cr-ethyl-Zoxo-1-pyrrolidineacetamide (5).

Drug codes: (R)-form: UCB L059, (S)-form: UCB L060, unspecified form: UCB 6474.


Molecular formula: C$_8$H$_{14}$N$_2$O$_2$.

Mol. wt.: 170.11 g/mol.

Beilstein cit.: ONLINE DIALOG BASE 390, Record No. 1529106.

First reported/first reported as nootropic: unspecified form: 1971 (ref. 343) (R)-form: 1985 (ref. 105), (S)-form: 1985 (ref. 105), (S)-form: 1985 (ref. 104).

Preparation: refs. 104, 105, 343 and 366

Physical data (melting point): unspecified form: m.p. 122°C (refs. 343,366).

2.7.2. **Antiamnesic and memory-enhancing properties of etiracetam**

Table 5 summarises selected antiamnesic and memory-enhancing properties of etiracetam. See the text for discussion.

2.7.3. **Interaction with acetylcholine neurotransmission**

UCB L059, known as (S)-etiracetam (54 mg/kg i.p., mice), ameliorates the amnesic effect of scopolamine (3 mg/kg i.p.) whereas its enantiomer UCB L060, (R)-etiracetam, has no effect. (S)-Etiracetam completely antagonises the amnesia when administered repeatedly\textsuperscript{376}.

The amnesic effect of i.c.v. hemicholinium-3 in mice is also reversed\textsuperscript{73}, whereas the hemicholinium-3-induced ACh depletion is not reversed\textsuperscript{73,400}.

(S)-Etiracetam causes contraction of a guinea pig ileum preparation in a dose-dependent manner, the contraction being inhibited by atropine, tetrodotoxin and by ACh depletion, but potentiated by AChE inhibition with physostigmine. (S)-Etiracetam does not af-
Table 5

Effect of etiracetam on various types of chemically/physically induced amnesia, lethality and recovery after insult

For an explanation of terms used, see Table III.

<table>
<thead>
<tr>
<th>Treatment/Measure</th>
<th>Species</th>
<th>etiracetam [mg/kg*]</th>
<th>Effect</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>None:</td>
<td>Learning Rats 20-30 i.p.</td>
<td>1 393</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Learning Rats 20-30 i.p.</td>
<td>1 394</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Modulation of ACh neurotransmission:</td>
<td>Passive Mice 30, 100 i.p.</td>
<td>RE 73</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemicholinium-3:</td>
<td>1.5 µg i.c.v. per hemisphere</td>
<td>376</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scopolamine:</td>
<td>3 i.p.</td>
<td>AA 376</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1.5 µg i.c.v. per hemisphere</td>
<td>Passive Mice 314</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Passive Mice 3, 54 i.p.</td>
<td>NE 376</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECS:</td>
<td>50 i.p.</td>
<td>AA 314</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypoxia:</td>
<td>5.5 p.o.</td>
<td>1 104</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Effect AChE activity. Regeneration of twitch response after hemicholinium-3/veratridine preinduced ACh depletion is facilitated by (S)-etiracetam, but not by (R)-etiracetam. This effect was not further augmented by coadministration of choline. The facilitated twitch recovery after administration of (S)-etiracetam was inversely correlated to the concentration of Ca\(^{2+}\) in the medium.\(^{400}\)

These results could indicate some facilitatory effect of (S)-etiracetam on the release of ACh. Wulfert et al.\(^{400}\) further suggest that the facilitated twitch recovery is especially pronounced in the absence of calcium-dependent ACh release (see also subsection 3.1).

2.7.4. Other effects

Etiracetam (170 mg/kg i.v., rabbits) is effective against severe barbiturate (80 mg/kg i.v.) intoxication, while piracetam does not confer any protection.\(^93\)

(R)-Etiracetam has been shown to be active against ECS induced amnesia in rats.\(^{105}\)

The EEG pattern dependency on etiracetam treatment has been investigated in man.\(^{307}\) In elderly people and patients with memory deficits the EEG is dominated by an increase in 2 and 0 activity and less a and 2-adjacent 6 activity compared to the activity seen in healthy persons. Etiracetam is capable of reversing these effects, leading to higher vigilance.\(^{305}\)

2.8. Nefiracetam

2.8.1. Chemical, bibliographic and historical data

Synonyms: 2-Oxopyrrolidineacetic acid, 2,6-dimethyl-anilide (6).
200 A. H. Gouliaev, A. Seming / Brain Research Reviews 19 (1994) 180-222

Drug code: DM-9384.
Molecular formula: C_{14}H_{18}N_{2}O_{4}.
Mol. wt.: 246.31 g/mol.
First reported/first reported as a nootropic: 1980 (ref. 21).
Preparation: ref. 21.

2.8.2. Pharmacokinetics

The metabolism of nefiracetam has been investigated in man[7,77,78] (Fig. 4); it is initiated by extensive hydroxylation of the pyrrolidone ring and of the phenyl group. The hydroxylated compounds are subsequently subject to further degradation or sulfate conjugation. The main metabolites of nefiracetam have been identified as N-(2,6-dimethylphenyl)-4-hydroxy-2-pyrrolidinone (MH-4 in Fig. 4), N-(2,6-dimethylphenyl)-5-hydroxy-2-pyrrolidinone (MH-2 in Fig. 4) and N-(2,6-dimethylphenyl)carbamoylmethylsuccinamic acid (MH-9 in Fig. 4)77. Cleavage of the pyrrolidone ring, leading to N-(2,6-dimethylphenyl)carbamoylmethyl-GABA, was not observed and less than 8% of the orally administered dose was excreted unchanged in the urine76.

The peak serum concentration (10 nM) was reached 2 h after a low dose of nefiracetam (100 mg p.o., man).

2.8.3. Antiamnesic and memory-enhancing properties of nefiracetam

Table 6 summarises selected antiamnesic and memory-enhancing properties of nefiracetam (see the text for discussion).

2.8.4. Interaction with γ-aminobutyric acid neurotransmission

The role of GABA in memory mechanisms is not completely understood. Picrotoxin is known as a GABA_A receptor-related chloride channel blocker and inhibits GABA neurotransmission. Picrotoxin and bicuculline (a GABA_A antagonist) can induce impairment of memory consolidation222,223,226. This impairment of memory consolidation can be reversed by administration of GABA agonists223.

Picrotoxin and bicuculline can, however, be shown to improve memory consolidation222 and picrotoxin may facilitate acquisition226. Furthermore, the GABA_A agonist muscimol, administered before training, causes amnesia222, whereas post-training treatment attenuates amnesia induced by scopolamine, cycloheximide and GABA antagonists226, but can also be shown to result in amnesia239.

Further complicating is the fact that post-training intraamygdala microinjection of the GABA_B agonist baclofen impairs memory (see Izquierdo and Medina138 for references) whereas inhibition of GABA_B autoreceptors (which down regulate the release of GABA) blocks the induction of LTP25.

A complicating factor is also the effect of anxiety during testing, since it is known that a high level of anxiety causes enhanced release of endogenous benzodiazepine receptor ligands from the amygdala, septum and hippocampus, which inhibits the memory consolidation process (see refs. 138, 140 and 182 for references and discussion of endogenous benzodiazepine receptor ligands and learning/memory).

Binding studies and bicuculline experiments suggest that nefiracetam might attenuate the drug-induced im-
pairment of memory consolidation through a direct or indirect interaction with GABA receptors. Ethanol is known to interact with the GABA-benzodiazepine-chloride channel receptor complex and thereby to enhance its affinity for benzodiazepines. Results with the benzodiazepine agonist chlorodiazepoxide (CDP) and ethanol-induced amnesia also seem to support a mechanism in which nefiracetam interacts with GABA receptors and not through muscarinic and benzodiazepine receptors, since the attenuation by nefiracetam of CDP and ethanol-induced amnesia is antagonised by bicuculline, but not scopolamin or the benzodiazepine antagonist flumazenil.

Nefiracetam inhibits the decrease in the number of GABA receptors caused by cycloheximide in rats.

Nefiracetam increases the activity of GAD and the turnover of GABA in the cortex, indicating an increase in the activity of GABAergic neurons.

The results achieved with nefiracetam on the GABA receptor system are difficult to interpret (see also Sarter) because of the unresolved influence of GABA on the memory process. Furthermore, the concentration of picrotoxin used by Nabeshima et al. was 3 mg/kg (s.c.), quite high compared to the LD50 value in mice of 4-7 mg/kg (i.p.). Finally, it is important to stress that the above-mentioned attenuation of amnesia did not exceed a level of about 50%.

2.8.5. Interaction with acetylcholine neurotransmission

Scopolamine is able to inhibit the antiannemetic effect of nefiracetam on cycloheximide, but not CDP-induced amnesia. This suggests that muscarinic receptors play a different role in these two situations. Nefiracetam is, however, capable of attenuating amnesia induced by hemicholinium-3 and scopolamine alone and nefiracetam increases the turnover of ACh in the cortex.

Nefiracetam (1-30 mg/kg p.o.) does not affect the ACh level, but attenuates the depletion induced by scopolamine in murine hippocampus, frontal cortex, amygdala and striatum more than physostigmine.

Nefiracetam increases the number of muscarinic receptors in rats.

Treatment of rats with nefiracetam caused an increase in CAT activity in the fronto-parietal cortex, but antagonised only slightly the marked fall in the activity of cerebrocortical CAT in another study.

2.8.6. Interaction with noradrenaline / dopamine / 5-hydroxytryptamine neurotransmission

A decrease in the tissue DA level and an increase in the HVA/DA level is observed in the striatum, whereas the opposite is observed in the hippocampus after ischemia in gerbils. Nefiracetam does not affect these ischemic effects.

During ischemia a decrease in the tissue level of NA and an increase in MHPG/NA can be observed in the hippocampus, hypothalamus and colliculus superior in gerbils. Nefiracetam was unable to counteract the decrease in NA level, but some attenuation of the increased MHPG/NA level was observed at 30 mg/kg nefiracetam in the hypothalamus.

A decreased tissue 5-HT level and an increased 5-HIAA/5-HT level is observed in several brain areas except the cortex after ischemia in gerbils. No major effect of nefiracetam on these phenomena could be observed, except for a small increase in the 5-HT content in the striatum.

2.8.7. Interaction with protein / lipid metabolism

Nefiracetam has been shown to inhibit amnesia induced by the protein synthesis inhibitor cycloheximide which, inter alia, causes a decrease in the number of GABAergic and muscarinic receptors. Nefiracetam inhibits the decrease in the number of GABA receptors and increases the number of muscarinic receptors.

Nefiracetam's reversal of the action of cycloheximide seems to involve GABA and ACh receptors since, as previously mentioned, the amnesia reversal was inhibited by picrotoxin, bicuculline and scopolamine, whereas the reversal of amnesia by CDP as already mentioned only seems to involve GABA receptors.

2.8.8. Other effects

Improvement is observed in old rats treated with nefiracetam (30 mg/kg p.o.) of active avoidance performance and nefiracetam has been suggested as an effective drug against SDAT.

Nefiracetam shows a bell-shaped dose-response curve, and nefiracetam attenuates ischemia-induced decreases in ATP and pyruvate/lactate ratio, but does not influence the glucose uptake and utilisation in normal mice.

At first glance one is struck by the resemblance between nefiracetam (6) and the local anaesthetic procaine.

Local anaesthetic properties of nefiracetam could perhaps explain the protective properties of nefiracetam, but there is a significant difference between it and typical local anaesthetics. Nefiracetam contains a carbonyl group in position 2 of the pyrrolidine ring and thus the amino group which is necessary for local anaesthetic effects by channel blockade is transformed into an amide group which is very much less basic, probably with less of all channel blocking effects.

2.9. Aniracetam

2.9.1. Chemical, bibliographic and historical data

Synonyms: 1-(4-methoxybenzoyl)-2-pyrrolidinone, 1-(p-anisoyl)-2-pyrrolidinone (7).
Table 7
Effect of aniracetam on various types of chemically/physically induced amnesia, lethality and recovery after insult
For an explanation of terms used, see Table 3.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Measure</th>
<th>Species</th>
<th>[aniracetam] mg/kg</th>
<th>Effect</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>None:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Active</td>
<td>Rats 100 p.o. D</td>
<td>NS</td>
<td>88</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Passive</td>
<td>Rats 1-300 p.o</td>
<td>NS</td>
<td>59</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Passive</td>
<td>Rats 30, 50 i.p. D</td>
<td>I</td>
<td>401</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Learning Monkeys 12.5, 25, 50 p.o. A</td>
<td>I</td>
<td>278</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Learning</td>
<td>Rats 50 i.p.</td>
<td>I</td>
<td>262</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Maze</td>
<td>Rats 100-800 p.o. A</td>
<td>I</td>
<td>193</td>
</tr>
<tr>
<td>Modulation of GABA neurotransmission:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Picrotoxin 3 s.c. B</td>
<td>Passive</td>
<td>Rats</td>
<td>15-90 p.o. A</td>
<td>NS</td>
<td>222</td>
</tr>
<tr>
<td></td>
<td>Passive</td>
<td>Rats</td>
<td>15-90 p.o. B</td>
<td>NS</td>
<td>222</td>
</tr>
<tr>
<td>Bicuculline 2 s.c. B</td>
<td>Passive</td>
<td>Rats</td>
<td>30-90 p.o. A</td>
<td>AA</td>
<td>222</td>
</tr>
<tr>
<td></td>
<td>Passive</td>
<td>Rats</td>
<td>30-60 p.o. B</td>
<td>AA</td>
<td>222</td>
</tr>
<tr>
<td>Chloralhydrate (CDP)</td>
<td>Passive</td>
<td>Mice</td>
<td>5-30 p.o. A</td>
<td>NS</td>
<td>226</td>
</tr>
<tr>
<td>Modulation of ACh neurotransmission:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scopolamine 0.63 i.p. A</td>
<td>Passive</td>
<td>Rats</td>
<td>100 p.o. A</td>
<td>RE</td>
<td>336</td>
</tr>
<tr>
<td></td>
<td>Passive</td>
<td>Rats</td>
<td>300 p.o. A</td>
<td>NS</td>
<td>336</td>
</tr>
<tr>
<td></td>
<td>Learning</td>
<td>Rats</td>
<td>10-100 p.o.</td>
<td>AA</td>
<td>243</td>
</tr>
<tr>
<td></td>
<td>Maze</td>
<td>Rats 10, 30 p.o.</td>
<td>AA</td>
<td>348</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Maze</td>
<td>Rats 10, 20 p.o. A</td>
<td>RE</td>
<td>136</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Learning</td>
<td>Monkeys 12.5, 25, 50 p.o. A</td>
<td>RE</td>
<td>278</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Learning</td>
<td>Monkeys 12.5, 25, 50 p.o. A</td>
<td>RE</td>
<td>278</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Passive</td>
<td>Rats</td>
<td>100 p.o.</td>
<td>RE</td>
<td>60</td>
</tr>
<tr>
<td></td>
<td>Passive</td>
<td>Rats</td>
<td>1-30 p.o. A</td>
<td>AA</td>
<td>302</td>
</tr>
<tr>
<td>Hemicholinium-3 119 i.p. A (LD50)</td>
<td>Lethality</td>
<td>Mice</td>
<td>300 i.p. A</td>
<td>RE</td>
<td>116</td>
</tr>
<tr>
<td>Modulation of NA neurotransmission:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clonidine 0.1 i.p. B</td>
<td>Active</td>
<td>Rats</td>
<td>50 D</td>
<td>RE</td>
<td>175</td>
</tr>
<tr>
<td></td>
<td>Passive</td>
<td>Rats</td>
<td>50 D</td>
<td>RE</td>
<td>86</td>
</tr>
<tr>
<td></td>
<td>0.1 i.p. Diethylthiobis-thiobutylamine (DEC)/</td>
<td>Passive</td>
<td>Rats</td>
<td>50 D</td>
<td>RE</td>
</tr>
<tr>
<td></td>
<td>potassium ethylxanthogenate (PEX) 300 i.p. (DEC)</td>
<td>Passive</td>
<td>Rats</td>
<td>50 D</td>
<td>RE</td>
</tr>
<tr>
<td></td>
<td>100 i.p. (PEX)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inhibition of protein synthesis:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cycloheximide (CXM) 30 s.c. B</td>
<td>Passive</td>
<td>Mice</td>
<td>3-30 p.o. ABC</td>
<td>AA</td>
<td>227</td>
</tr>
<tr>
<td>ECS:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Maze</td>
<td>Mice</td>
<td>20 p.o. A</td>
<td>RE</td>
<td>136</td>
</tr>
<tr>
<td></td>
<td>Passive</td>
<td>Rats</td>
<td>10 p.o. A</td>
<td>AA</td>
<td>302</td>
</tr>
<tr>
<td>Hypoxia:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Learning</td>
<td>Man</td>
<td>10, 100 iv. B</td>
<td>AA</td>
<td>306</td>
<td></td>
</tr>
<tr>
<td>Learning</td>
<td>Rats</td>
<td>32, 100 p.o.</td>
<td>AA</td>
<td>243</td>
<td></td>
</tr>
<tr>
<td>Passive</td>
<td>Mice</td>
<td>2-30 p.o.</td>
<td>RE</td>
<td>348</td>
<td></td>
</tr>
<tr>
<td>Passive</td>
<td>Rats</td>
<td>30 p.o.</td>
<td>AA</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>Other:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Basal forebrain lesion</td>
<td>Maze</td>
<td>Rats</td>
<td>3, 10 p.o. A</td>
<td>AA</td>
<td>225</td>
</tr>
<tr>
<td></td>
<td>Passive</td>
<td>Rats</td>
<td>3, 10 p.o. A</td>
<td>NS</td>
<td>225</td>
</tr>
</tbody>
</table>
Drug code: Ro 13–5057.
Molecular formula: C_{12}H_{15}NO_3.
Mol. wt.: 219.10 g/mol.
Martindale ID: 1651 l-s.
First reported/first reported as nootropic: 1979 (ref. 127).
Preparation: ref. 127
Physical data (melting point): m.p. 121–122°C (from ethanol)\(^27\).
LD\(_{50}\): 4.5 g/kg p.o. (rats), 5.0 g/kg p.o. (mice)\(^53\).

2.9.2. Clinical findings
Aniracetam has recently been shown to improve the condition of elderly patients suffering from slight to moderate mental deterioration (1.5 g daily)\(^36\), of geriatric patients with cerebrovascular insufficiency\(^70\) and in one SDAT study\(^324\) while aniracetam showed no effect (1 g daily for 3 months) in patients who suffered from long-term exposure to organic solvents\(^331\) and in another SDAT study\(^332\).

2.9.3. Pharmacokinetics
Aniracetam is absorbed very rapidly from the GI after p.o. administration, but its bioavailability is low due to extensive first-pass metabolism. According to Guenzi and Zanetti\(^115\), the total body clearance of aniracetam is as high as 10 l/min. The imide compounds aniracetam and rolziracetam are quite unstable in vivo and are transformed to the more stable amide and acid. In humans the main metabolite of aniracetam is N-anisoyl-GARA (70%) and the remaining 30% appear as 4-methoxybenzoic acid and 2-pyrrolidinone\(^115\).

2.9.4. Antiamnesic and memory-enhancing properties of aniracetam
Table 7 summarises selected antiamnesic and memory-enhancing properties of aniracetam. See the text for discussion.

2.9.5. Interaction with g-aminobutyric acid neurotransmission
Aniracetam affects GABA receptors weakly. It only ameliorates (maximally about 33%) bicuculline-induced amnesia, but not CDP induced amnesia and is unable to reverse picrotoxin-induced amnesia\(^222,226\). Finally, the response of GABA receptors to GABA, at 1 mM aniracetam, is not affected\(^135\).

2.9.6. Interaction with glutamate neurotransmission
Micromolar amounts of aniracetam enhance the efficacy, but not the potency, of AMPA-induced calcium influx in cerebellar granule cells, an effect which persists in the presence of the voltage sensitive l-type calcium channel blocker nifedipine\(^48\). Aniracetam does not change the receptor binding affinity for AMPA nor the ion conductance selectivity\(^135\).

Aniracetam only affects the fast synaptic currents mediated by the ionotropic quisqualate receptor and only AMPA, but not NMDA or kainate. EPSC is enhanced by aniracetam (0.1–5 mM)\(^135,151,249,349\). Piracetam and 2-pyrrrolidinone were inactive\(^135\). (See also discussion in subsection 2.1.6).

The decay of glutamate-induced EPSCs is slowed 2–3 fold and the magnitude of stimulus evoked EPSC is doubled by aniracetam. l-Glutamate activated single channel response lengths are increased by aniracetam and aniracetam (10\(^{-5}\)–10\(^{-7}\) M, but not 10\(^{-6}\) M) augments LTP in the hippocampal CA3 area\(^318\).

Simulations suggest that aniracetam acts via a post-synaptic mechanism by slowing the entry into a desensitised state, decreasing the rate constant for ion channel gating\(^135,151,249,349,385\) or, as suggested for oxiracetam, by recruitment of a subset of AMPA receptors which do not normally contribute to synaptic transmission\(^48\). Recently it was shown that the mechanism underlying LTP formation in the guinea pig hippocampal CA1 region is unrelated to aniracetam’s enhancement of EPSC (ref. 10).

2.9.7. Interaction with acetylcholine neurotransmission
Aniracetam exerts its effect on scopolamine-induced amnesia in a dose responsive manner, since 10–100 mg/kg p.o. to rats ameliorates amnesia\(^90,120,243,278,297,348,377\) whereas a dose of 300 mg/kg p.o. is less effective or without effect\(^336,358\). Furthermore, the scopolamine-induced decrease in striatum, cerebral cortex and hippocampal ACh content is ameliorated in the hippocampus and the cerebral cortex by aniracetam (100–300 mg/kg p.o., rats)\(^336,358\). Aniracetam (100–300 mg/kg p.o., rats) also increases the ACh content in the absence of scopolamine-induced depletion in the hippocampus and the cerebral cortex, but not in the corpus striatum. The choline content is neither increased in the hippocampus nor in the corpus striatum\(^58\) and sodium-dependent high-affinity choline uptake is not affected by aniracetam (10–200 mg/kg p.o., rats)\(^326\). Aniracetam (10–100 \(\mu M\) in hippocampal slices\(^203\) does not affect CAT activity in hippocampal slices\(^203\).

Finally, i.p. injection of pirenzepine, an M\(_1\) selective antagonist, results in contralateral turning behaviour in mice which can be reversed by muscarinic agonists, AChE inhibitors and aniracetam, but not by the GABA\(_A\) agonist muscimol or the 5-HT uptake inhibitor citalopram, nor by the \(\alpha\)-sympathomimetic amphetamine\(^397\).
2.9.8. Interaction with noradrenaline / dopamine / 5-hydroxytryptamine neurotransmission

It has been reported that aniracetam (50 mg/kg p.o., rat) decreases the DA level in the striatum and the hypothalamus. This is probably not due to the fact that aniracetam activates monoamine oxidase B (MAO_B), but inhibits MAO_A in the striatum and the hypothalamus, since dopamine seems to be a substrate of both enzymes. The overall effect on MAO is inhibition and the decrease in DA level could therefore indicate an increased release of DA.

A study on the effect of prolonged aniracetam administration (50 mg/kg, p.o., b.i.d., 7 days, rats) on peripheral adrenergic neurons in blood vessels has been performed. It seems that some modulation of the contractile response to NA is possible, mostly as a potentiating effect.

Activation of α_2 receptors by clonidine induces memory impairment whereas blockade of these receptors by, e.g., atipamezole improves memory retention, but not retrieval of memory. Aniracetam reverses the memory impairment induced by clonidine. Likewise aniracetam (50 mg/kg p.o., 5 days, rats) completely abolishes the amnesic effect of the dopamine β-hydroxylase inhibitor N,N-diethyldithiocarbamate and potassium ethylxanthogenate.

The 5-HT level is decreased in the hypothalamus, but increased in the cortex and the striatum by aniracetam (50 mg/kg p.o., rats). 5-HT turnover was delayed in the hypothalamus, but accelerated in the cortex, brain stem and striatum.

The decrease in brain biogenic monoamine content with age is ameliorated by aniracetam.

2.9.9. Interaction with steroids

Adrenalectomy, inhibition of steroid biosynthesis by aminoglutethimide and blockade of aldosterone receptors by epoxymexrenone completely suppress the memory improving effect of aniracetam (see previous discussion in subsection 2.1.9).

2.9.10. Interaction with protein / lipid metabolism

Aniracetam antagonizes the amnesia induced by the protein synthesis inhibitor cycloheximide.

2.9.11. Other effects

Aniracetam inhibits (K_i = 160 μM) prolylendopeptidase (PEP) in the mesencephalon, striatum, cerebellum, hippocampus and hypothalamus, but is inactive in the cerebral cortex and the medulla oblongata.

Aniracetam is well tolerated, has no influence on food and fluid intake and does not affect locomotor activity in rats. No physical or psychic dependence is observed in monkeys.

2.10. Analogues of aniracetam

2.10.1. Phenyl-substituted analogues

The p-fluoro, p-chloro, p-demethoxy- and p-(2-oxopyrrolidinyl)-analogues of aniracetam have been prepared and tested; they cause improvement of memory consolidation.

2.10.2. 1-Acyl-2-pyrrolidinones

1-Valproyl-2-pyrrolidinone has been prepared and tested. This compound ameliorates scopolamine-induced amnesia, protects against hypoxia and reduces the glutamate and aspartate content in hippocampal slices.

Valproic acid is known as an antiepileptic drug, but with the amide being more effective than the acid. Since the main metabolite of aniracetam is N-anisoyl-GABA one could expect the same for 1-valproyl-2-pyrrolidinone. A comparable metabolism would generate an amide of valproic acid. Further support is found in a study by Sasaki et al., showing anticonvulsant and anti-amnestic properties of a number of 1-acyl-2-pyrrolidinones, especially the 1-dodecanoyl derivative. They were shown to generate GABA after treatment with mouse liver homogenate in vitro.

2.10.3. 1-Sulfonyl-2-pyrrolidinones

2-Oxopyrrolidine-1-sulfonic acid derivatives have been prepared as analogues of aniracetam. Substituted 1-(phenylsulfonyl)-2-pyrrolidinones have been claimed to possess cognition enhancing properties whereas other 2-oxo-1-pyrrolidinesulfonic acid derivatives were devoid of activity in tests where aniracetam was active.

2.10.4. Other analogues of aniracetam

The 3-hydroxy-analogue of aniracetam has been tested in hyperventilation-induced EEG changes in young humans (1.5 g p.o.). It was as effective as aniracetam.

2.11. Rolziracetam

2.11.1. Chemical, bibliographic and historical data

Synonyms: tetrahydropyrrolizine-3,5-dione; 3,5-di-oxohexahydropyrrolizine; dihydro-1H-pyrrolizine-3,5-(2H,6H)-dione.

Drug code: CI-911.


Molecular formula: C_7H_8NO_2.

Mol. wt.: 139.15 g/mol.

Beilstein cit.: V 21/10, 69; IV 21/10, 4668.

First reported: 1947 (refs. 180,187).

First reported as nootropic: 1982 (ref. 32).

Spectroscopic data: refs. 1, 69, 199 and 373.

Physical data (melting points): m.p. 175–182°C (from ethanol)45, m.p. 176–177°C (from ethanol)180, m.p. 181°C (from benzene)180, m.p. 181.5–182°C (from ethanol)321, m.p. 181.5–182°C (from water)321, h.p. 173°C (665 Pa)45.

2.11.2. Pharmacokinetics

The metabolic disposition of rolziracetam has been investigated in monkeys, dogs and rats after both p.o. and i.v. doses23.

When rolziracetam is given i.v. it is eliminated rapidly from the systemic circulation, having a t1/2 of less than 25 min, leaving 5-oxo-2-pyrrolidinopropionic acid, the sole metabolite of rolziracetam, in circulation. The hydrolysis of rolziracetam is presumably mediated through nonspecific esterases/amidases which are distributed throughout the body. After oral doses only traces of intact drug can be detected in the plasma, but the metabolite is reaching peak levels 0.5–1 h after administration, indicating a fast absorption. Rolziracetam and its metabolite are excreted almost solely by renal elimination. Only small amounts concentrate in the brain because of the very polar structure of the metabolite23 (see Table II). The amount of rolziracetam reaching the brain may, however, be trapped there.

2.11.3. Interaction with acetylcholine neurotransmission

The amnesic effect of a high concentration of scopalamine (3 mg/kg i.p.), given to mice before an acquisition trial, could not be reversed by rolziracetam (14–460 mg/kg i.p.)376.

2.11.4. X-ray structure of rolziracetam

Rolziracetam has been subjected to an X-ray analysis13, but since it is rapidly transformed into the active metabolite 5-oxo-2-pyrrolidinopropionic acid in vivo, this structure analysis does not reveal anything about the structure of a potential receptor site.

2.12. Analogues of rolziracetam

Different analogues (27) and (28) of rolziracetam have been prepared and tested as antiamnesic compounds in ECS tests in mice23,32,34. The compounds were given after learning and ECS, but before the retention test.

It seems that the 5,5- and 5,6-ring systems possess equal activity. The 5,7- and 6,6-bicyclic compounds displayed less activity. Replacement of a methylene group by sulfur leads to compounds with less activity. 2-Methyl or 2,6-dimethyl derivatives were also less effective, whereas the 7a-methyl compound seemed more active. Reduction of one carbonyl group to an alcohol group gave a compound with less activity, perhaps because of increased stability towards hydrolysis.

The possible metabolites of the above-mentioned compounds have been synthesised and tested (29).

The length of the side chain has little influence on the activity. However, the compound with n = 2, corresponding to the metabolite of the parent 5,5-bicyclic compound, seems most active and the one with n = 1 least active. Esters and amides are somewhat less active than the corresponding acids. This is contrary to expectation, since the esters and amides should be more lipophilic.

Introduction of a sulfur atom or of a double bond in the side chain reduces the activity. The potency varied with the ring size of the lactams in the order 6- > 5- > 7-membered. The intrinsic activity of the 5-membered lactam was highest, it also showed the broadest activity range. Finally, the potential metabolites seemed more potent than the parent compounds23. In this context it is interesting that the compound with n = 0, m = 1 and R = OH corresponds to pyroglutamate the d-form of which possesses antiamnesic properties. Generally speaking there is a good correlation between the activities of the parent compounds and their metabolites.

3. General discussion

A great deal of different biochemical and behavioural findings have been presented throughout the years. As evident from the presentation above and up to now no key mechanism for the cognition enhancing and protective effect of these compounds has been established.

We would like to stress that there appears good reason to assume that the nootropics improve the cognitive state (see also Poschel265) by exerting effects on the brain activity. A few selected results taken from above should emphasise this.

The EEG of elderly people, of healthy volunteers treated with diazepam and of patients with memory deficits is dominated by an increase in δ and θ activity and less α and α-adjacent β activity compared to the activity seen in healthy persons. Aniracetam, piracetam and etiracetam are capable of reversing these effects, leading to greater vigilance30,304,305,313 and pramiracetam normalises the EEG pattern of aged rats towards that observed with young rats264,285.

3.1. Structure–activity relationships

If one looks at the structures involved it seems that they only have the pyrrolidine ring in common which also seems to be important for their activity. This is interesting, since 2-pyrrolidone has been found to occur naturally in man283. In the series of analogues of
piracetam, oxiracetam, pramiracetam and etiracetam it seems that the acetamide moiety is important for activity.

4-Hydroxy-substitution increases the potency, since lower doses of oxiracetam are often required for equipotency with piracetam. The hydroxy-group could well be involved in crucial hydrogen bonding since the corresponding alkoxy- and acyloxy-compounds are less active. Another possibility would be that oxiracetam is oxidised in vivo, which is very unlikely for the acyloxy- and alkoxy-analogues. Oxidised metabolites of oxiracetam have, however, not been observed in vivo.

N-Substitution, with crucial dependence on side chain length, as in the case of pramiracetam also increases the activity. Part of the increased activity might be due to higher lipophilicity. Interference with cation channels, due to the basic amino group, may also cause some effects.

Very interesting is the stereospecificity of the biological action of etiracetam. This fact may well turn out to be a powerful tool in the elucidation of the mechanism of action. Only the (S)-form of etiracetam ameliorates the amnesic effect of scopolamine, as mentioned above. Biochemical experiments should therefore be conducted with the pure enantiomers of etiracetam. Biochemical findings which show significantly higher activity of the (S)-form at clinically relevant concentrations could very well be linked to the aniansmic action of these compounds, but the possibility of a stereospecific transport mechanism for etiracetam can, of course, not be ruled out. Unfortunately, this powerful tool has not been used much (only two studies376,400 have been conducted so far with the pure enantiomers). The apparent stereospecificity should, however, perhaps be regarded with caution, since (R)-etiracetam has been shown to be active against ECS induced amnesia (the (S)-form was not tested)105.

The structure–activity relationships for aniracetam and rolziracetam have been discussed above. When considering structure–activity relationships for these one should bear in mind the rapid metabolism in vivo, leading to γ-carbonylamino butyric acid structures. In vitro and in vivo results are therefore not necessarily well correlated (see Sasaki et al.317 for the stability of acylpyrrolidinones in different media).

Finally, the study by Gudasheva et al.114 should be recalled. Ligands for possible nootropic binding sites in the brain are likely to resemble proline or pyroglutamate.

3.2. Mechanisms of action

In this section we present a short discussion of previously suggested mechanisms of action followed by our own view on a possible mechanism of action, based on the available evidence.

3.2.1. Previously suggested mechanisms of action

It has been proposed in the literature that the piracetam-like nootropics should exert their effect by a nonspecific action, but it seems more reasonable to assume a specific mode of action, since the piracetam-like nootropics exhibit bell-shaped dose response curves (see, e.g., refs. 33, 286, 289, 336, 358 and 285).

Thus, Poschel et al.285 observed a therapeutic window with pramiracetam for changes of EEG (1–160 mg/kg p.o., rats), learning behaviour (1–160 mg/kg p.o., rats) and single neuron (ventral pallidum) firing rates (2–16 mg/kg i.v., anaesthetized (ketamine) rats) and the decrease in activity at higher doses were shown not to be due to toxic effects.

The bell-shaped dose–response relationships are, however, not unique to the piracetam-like nootropics, since they have also been observed in behavioral studies with other cognitive activator agents (see Pugsley et al.289 for references).

The stereospecific biological action observed in the case of etiracetam and the fact that oxiracetam is subject to saturable binding in the rat brain190,247 also supports a specific mode of action.

From Table 1 it is, however, evident that the piracetam-like nootropics do not exhibit high affinity for any of the receptor types tested so far (except for nefiracetam, which shows some activity at GABA_A receptors) and they do not share any of the side effects associated with analeptics or psychostimulants (see refs. 5, 92 and 95 for a discussion of drug classification and 49, 122 for a comparison of nootropics, psychostimulants and analeptics).

There has been much discussion on whether the racetams exert their effect by a centrally or by a peripherally mediated mechanism. It would be attractive and, of course, straightforward to link the amnestic action of these compounds to their centrally mediated effects, but how can we then account for the peripheral effects observed?

Investigations like those of Mennini et al.106 and Taddei et al.347 who observed saturable binding of oxiracetam in the rat brain, support a centrally mediated mechanism of action and in the early years of investigation it was also suggested that piracetam should act selectively on telencephalic functions, since it lacks reticular and limbic effects as well as activity on hypothalamic and pituitary functions93.

Further indications for a centrally mediated mechanism of action arise from the fact that even the least lipophilic compounds like piracetam and oxiracetam (see Table II) are capable of entering the CNS, al-
though with some delay, but then with longer half-lives in the brain. They alter the EEG pattern, i.e., injection of, e.g., oxiracetam is able to reverse scopolamine-induced amnesia which also can be reversed by the cholinomimetics physostigmine, oxotremorine and the nootropic pramiracetam, but not the peripherally acting cholinomimetic neostigmine and anticholinergic methylatropine.

Much interest has been devoted in the literature to a possible cholinergic mechanism for the actions of the racetams (see Pepeu and Spignoli for a review on piracetam-like nootropics and cholinergic mechanisms). The cholinergic system, however, is probably not directly affected by the racetams and Mondadori et al. have investigated the effects of different drugs on the memory consolidation process at different times after a learning trial. The results of this study reveal that stimulation of memory consolidation through a blockade of strychnine-sensitive glycine receptors is possible up to 1 h after a learning trial whereas stimulation of memory consolidation through the cholinergic system is feasible up to 2 h after a learning trial. The piracetam-like nootropics (piracetam, oxiracetam, pramiracetam and aniracetam) stimulate the memory consolidating process up to 8 h after a learning trial.

The piracetam-like compounds do, however, exert some effects (probably of secondary origin, see below) on the cholinergic system such as, e.g., reversal of scopolamine or hemicholinium-3-induced amnesia and even the peripheral cholinergic system is susceptible to their effects such as reversal of d-tubocurarine-induced neuromuscular blockade and lethality due to neuromuscular paralysis by hemicholinium-3.

Furthermore, the action of the piracetam-like nootropics is, as previously mentioned, dependent on steroids. This is not the case for the cholinomimetics arecoline and physostigmine.

Mondadori et al. suggest that activation of aldosterone receptors might be an absolute prerequisite for any nootropic effect or that the piracetam-like nootropics might modulate the effect of steroids on memory.

The steroid dependency, together with the above mentioned time dependency, would indeed imply that the piracetam-like nootropics have effects beyond an action on the cholinergic system which may then be classified as secondary, but nonetheless very important, effects.

On the other hand, the cholinomimetics and the nootropics share the property of inhibition of their activity by high steroid levels.

3.2.2. Modulation of ion fluxes, the mechanism of action?

The question is how to account for the somewhat puzzling fact that the racetams are capable of influencing so many different processes and still being so nontoxic.

Most of the various biochemical findings such as, e.g., effects on MAO, HACU, protein and lipid metabolism, are in our view probably secondary to some specific primary effect and we think that the racetams exert their effect on some species present in the membranes of all excitable cells, i.e., the ion carriers or ion channels and that they somehow accomplish an increase in the stimulatory response. This is supported by observations like the piracetam reversal of d-tubocurarine-induced neuromuscular blockade by a combined effect of an increase in neurotransmitter release and excitability of motor nerve terminals.

Such effects could be a consequence of, e.g., increased sodium influx, decreased potassium efflux or increased calcium influx and could explain the observed augmentation of LTP seen at very low doses (10–100 nM) of aniracetam and oxiracetam’s enhancement of depolarisation induced glutamate release. Furthermore, these effects are linked to the nerve impulse as observed by Marchi et al. since, e.g., etiracetam’s effect on guinea pig ileum contraction is completely blocked by the sodium channel blocker tetrodotoxin while oxiracetam increases the release of glutamate induced by depolarisation, but not the spontaneous release.

As described in subsection 2.1.9, the piracetam-like nootropics show a dependency of their beneficial effect on the stimulation of aldosterone receptors. One possible explanation, in the case of adrenalectomised animals, would then be an electrolyte imbalance caused by a cation transmembrane transport change in the kidneys which could have been counteracted by the administration of aldosterone to the adrenalectomised animals for 8 days, causing the beneficial effects of the nootropics to reappear.

This would also require some electrolyte imbalance to appear 26 h after treatment with the aldosterone antagonist epoxymexenone and the steroid synthesis inhibitor aminoglutethimide, since these also inhibit the beneficial effect of the piracetam-like nootropics. Other reasons for the dependence on aldosterone receptor stimulation can, of course, not be excluded.

Some effect on ion fluxes is supported by the fact that the activity of the Na+/K+-ATPase decreases in vivo after treatment with high doses of piracetam (600 mg/kg daily for 30 days, rats). The transport carrier is not affected in vitro, probably indicating that it is not a question of direct allosteric inhibition of the carrier. A decrease in activity could perhaps indicate a decrease in the number of carriers.

It would therefore seem that the racetams act as potentiators of an already present activity (also causing the increase in glucose utilisation observed) rather than possessing any activity of their own, in keeping
with their very low toxicity and lack of serious side effects. The result of their action is therefore an increase in general neuronal sensitivity towards stimulation.

Such a link between the effect of the nootropics and an already present activity would also explain why different results have been observed under different experimental conditions, such as, e.g., the dependence on the intensity of the foot shock used to the learning ability of the animals to be tested. Active avoidance tests, passive avoidance tests, mazes and other learning systems may cause different neurochemical events and may cause anxiety or arousal to a different extent, which would influence the neuronal activity and thereby the experimental parameter to be measured.

An increased basal activity would also be expected to increase the effect of the piracetam-like nootropics, which is seen in the case of co-treatment with oxiracetam and methamphetamines, nicotine, or the presynaptic muscarinic blocker scopolamine. An enhancement of stimulatory pathways would also counteract the inhibitory effects of, e.g., barbiturates and scopolamine.

The question is now which kind of ion transport mechanism is affected.

The decay of glutamate induced excitatory postsynaptic currents (EPSCs) is slowed, the magnitude of EPSC enhanced and l-glutamate activated single channel response lengths are increased by aniracetam. Simulations suggest that aniracetam acts via a postsynaptic mechanism by slowing the transition to a desensitised state, thus decreasing the rate constant for ion channel gating. This could be an indirect indication of increased sodium or calcium influx.

The results by Wülfer et al. showed that the effect of etiracetam on twitch recovery after ACh depletion in the guinea pig was inversely correlated to the extracellular calcium concentration. It is known that a modest decrease in the extracellular concentration of Ca$^{2+}$ can decrease excitation thresholds and could thereby synergise the effect of the piracetam-like nootropics.

Another possible mode of action would, as already mentioned, be via a decreased potassium efflux and piracetam has indeed shown to decrease potassium efflux from erythrocytes.

It is in this context interesting to note some of the structural similarities between piracetam, oxiracetam, pramiracetam, etiracetam, nefiracetam and the potassium channel openers of the benzopyran type, e.g., lemakalim. A comparison of these nootropics with lemakalim shows that the unionisable hydroxy-group in position 3 of lemakalim has been exchanged for an unionisable amino group in the form of an amide moiety in the nootropics. Furthermore the active (S)-form of etiracetam (31) has an absolute configuration opposite to that of lemakalim (30). It would therefore be interesting to clarify whether the observed changes result in a potassium channel closing activity of the nootropics compared to the channel opening activity of lemakalim.

One may further speculate whether the effect of the piracetam-like nootropics involves receptor gated channels, voltage-dependent channels or ion carriers.

Aniracetam, piracetam and oxiracetam enhance, as previously mentioned, selectively the efficacy, but not the potency, of AMPA-induced calcium influx in cerebellar granule cells without change in ion conductance selectivity and Ito et al. imply that the effect of aniracetam should resemble the glycine-NMDA receptor interaction and not the benzodiazepine-GABA receptor interaction, since the latter changes its affinity for agonists and is therefore more likely that aniracetam modifies the properties of the AMPA-associated cation channel.

Glutamate is the main excitatory neurotransmitter in the brain and a general increase in excitatory activity would also be expected to cause a general increase in the activity and turnover of other transmitters, but since the piracetam-like nootropics elicit both peripheral and central effects some effects have to be elicited through receptor gated channels or voltage-dependent channels present both centrally and peripherally.

It was shown recently that the mechanism underlying LTP formation in the guinea pig hippocampal CA1 region is unrelated to aniracetam's enhancement of EPSC (ref. 10), thus possibly indicating effects beyond the AMPA system.

The mediation of the possible effect on ion channels may be direct allosteric one, but action on G-proteins in G-protein modulated ion channels cannot, at present, be ruled out nor can a possible action on ion carriers.

The effect of compounds with the suggested mechanism, i.e., a potentiation of depolarisation evoked increase in sodium or calcium influx or by decreasing potassium efflux, would result in a potentiated release and response to depolarizing neurotransmitters, but only a potentiation in the release of inhibitory neurotransmitters.

The mechanism described would also explain the rather unusual bell-shaped dose response curves observed with these compounds, since the increase in response from depolarizing neurotransmission may be counteracted by an increase in the release of inhibitory neurotransmitters. This also means that at some ratio of excitatory/inhibitory activity no net response to the racetams may be seen, since the effect is fully counteracted. If on the other hand, there is, e.g., an increase in excitatory activity, this increase might be potentiated (cf. subsection 3.2.1).
Such a mechanism of action, i.e., a potentiation of neurotransmission, would demand some degree of activity present, otherwise no effect will be seen and effects should be especially pronounced in situations of physiological (or pharmacological) augmentation of specific neuronal pathways (e.g., in the learning/memory process) which would be further potentiated.

3.3. Clinical potential

The investigation of the beneficial effects of the racetams' presumed action as potentiators of neurotransmission has revealed that these effects are especially pronounced in situations of imbalance (e.g., a change in the normal excitatory/inhibitory ratio), but only to a certain degree. This would correlate well with the idea that they are dependent on activity already present.

In healthy subjects the beneficial effects also seem less pronounced, indicating some sort of negative feedback. Such negative feedback (e.g., by a potentiation in the release of inhibitory transmitters) might be present in subjects without any receptor plasticity deficits (see refs. 221, 372 and 396 for a discussion on the decrease in receptor plasticity with age).

The known decrease in receptor number, receptor sensitivity and receptor-effector coupling (coupling to secondary messenger systems) with age may be involved in the decreased receptor plasticity. The racetams increase the general activity, which may cause the racetam-induced increase in the receptor number seen in drug treated or old animals. This would then increase the synaptic efficacy and result in a generally improved performance.

Beneficial effects of these compounds are therefore to be expected in patients with mild to moderate dementia. In more progressed dementia the activity along some neuronal pathways may be so low that improvement is no longer to be expected (see also refs. 231 and 234). In the case of advancing dementia co-treatment with other drugs may very well be beneficial. The racetams' presumed action as potentiators of neurotransmission might also explain the benefit for Parkinson patients of treatment with piracetam. Since other single drug treatments are known to increase some specific neuronal transmission (e.g., L-Dopa reinforces the dopaminergic effects, physostigmine the cholinergic effects, etc.), co-treatment with piracetam-like compounds should especially potentiate these neuronal transmissions.

If the above described hypothesis, i.e., a potentiation of already present neurotransmission, accounts for the actual mechanism, other possible uses of the racetams could become interesting, especially in co-treatment with other drugs.

Possible examples of uses, beyond that in patients suffering from mild to moderate dementia, would then involve diseases such as myasthenia gravis (possibly as part of a co-treatment with AChE inhibitors), schizophrenia (possibly in a co-treatment regimen with neuroleptics, reducing the anticholinergic and extrapyramidal effects associated with the latter; increases in glutamic neurotransmission may increase the release of neurotransmitters, thereby further adding to the benefit), Parkinson's disease (possibly as co-treatment with L-Dopa, reducing the dose of L-Dopa needed and allowing to extend the time range of possible treatment with L-Dopa), depression (possibly as co-treatment with tricyclic antidepressants, reducing the amount of antidepressant needed and decreasing the anticholinergic side effects), epilepsy (co-treatment with valproate should increase GABA neurotransmission further) and in congestive heart failure (possibly by co-treatment with the Na⁺/K⁺-ATPase inhibitor ouabain).

3.4. Final comments

Discrepancies between the effects on memory in animal and human studies of nootropic compounds have been reported. This might be due to ill-defined patient collectives (see Gainotti et al.80), to progressed dementia in some patient collectives and to the concentrations used.

In animal experiments the amounts used are often much higher (often higher than 100 mg/kg) than the concentrations used in man (a dose of 2 g corresponds to about 20-40 mg/kg). The peak CSF total concentration (bound and free) reached in humans is about 10-15 μM after 2 g oxiracetam (p.o.). One should, however, remember that the piracetam-like nootropics exhibit a therapeutic window and overdosing is therefore possible. Finally, the piracetam-like nootropics in their present state of development seem to be most efficient in long-term treatment, which would allow beneficial effects on receptor plasticity.

It is, in general, also important to point out, as has been done by others (especially by Sarter315 and Sarter et al.316), that the choice of the animal model in screenings of possible cognition enhancing drugs (see Sarter315,316) is very important for the achievement of acceptable validity, i.e., in order to avoid confusion by false positive cognition enhancers.

We hope that our overview and critique of the available biochemical data will contribute to the generation and testing of new ideas concerning the mechanism of action of piracetam-related nootropics and, of course, especially tests of our working hypothesis.

We would therefore particularly like to encourage in vitro experiments such as, e.g., patch clamp experiments with the pure enantiomers of etiracetam.
Our final conclusion is that the establishment of the mechanism of action for these prototype compounds, followed by a full SAR investigation, would bode well for the development of drugs with well-balanced pharmacokinetics and activity and which as such or perhaps especially as part of a co-treatment regimen will be of benefit in cognitive disease states and also in additional indications.

Acknowledgements

The authors wish to express their gratitude to the ‘Direktør Erik Hørslev & Hustru Birgit Hørslevs Fond’ for financial support.

Abbreviations

ACE  angiotensin-converting enzyme  MAO  monoamine oxidase
ACH  acetylcholine  MHPG  3-methoxy-4-hydroxyphenylglycol sulfate
ACH-E  acetylcholinesterase  m.p.  melting point
ADH  adrenocorticotropic hormone  NA  noradrenaline
ADTN  2-amino-6,7-dihydro-1,2,3,4-tetrahydro-naphthaene  NMDA  N-methyl-D-aspartate
AMPA  \( \alpha \)-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid  PEP  prolylendopeptidase
AP-5  2-amino-5-phosphonoheptanoic acid  PKC  protein kinase C
AP-7  2-amino-7-phosphonoheptanoic acid  PLG  prolyllyceuglycine
ATP  adenosine 5'-triphosphate  p.o.  per oral
BBB  blood–brain barrier  QNB  quinuclidinyl benzilate
b.i.d.  bis in die  QSAR  quantitative structure–activity relationship
b.p.  boiling point  SAR  structure–activity relationship
CAT  choline acetyl transferase  s.c.  subcutaneously
CDP  chloridiazepoxide  SDAT  senile dementia of Alzheimer’s type
CNS  central nervous system  t.i.d.  ter in die
CSF  cerebrospinal fluid  TRH  thyrotropin-releasing hormone
5-HT  5-hydroxytryptamine  5-HIAA  5-hydroxyindoleacetic acid
5-HTP  5-hydroxytryptophan  HVA  homovanillic acid
HACU  high-affinity choline uptake  i.a.  intraarterially
5-HIAA  5-hydroxyindoleacetic acid  i.c.v.  intracerebroventricularly
HVA  homovanillic acid  i.p.  intraperitoneally
i.a.  intraarterially  i.v.  intravenously
i.v.  intravenously  LTP  long-term potentiation
References


29 Burov, Yu.V., Robakidze, T.N., Kadyshova, L.V., Voronin, A.E. and Shaposhnikova, G.I., Study of anti-annemic activity of amri-


54 Reference deleted.


63 Dudkin, S.M., Polev, P.V. and Soldatov, N.M., Calcium entry blockers and oxiracetam have opposite effects on the density of dihydropyridine receptors in rat cerebral cortex, Brain Res., 525 (1990) 319–321.


69 Flitsch, W., Einfluß der Ringgröße auf die Eigenschaften cyclischer imide, Chem. Ber., 97 (1964) 1548–1554 (pp. 1548, 1549, 1550, 1552).


75 Fujii, T., Kuraishi, Y., Ueda, M. and Satoh, M., Specific binding sites for bifemelane in the hippocampus of the guinea pig, relevant to its pharmacological actions, Neuropharmacology, 30 (1991) 1291–1295.


137 Izquierdo, I., Dopamine receptors in the caudate nucleus and memory processes, TIPS, 13 (1992) 7–8.


in hydrogen gas by C. K. H. W. the thermally sintered powders, a new type of sintering process which is characterized by its high temperature and low pressure. It has been found that the sintering temperature can be greatly reduced by using this new process. The sintered powders are then cold isostatically pressed and sintered again at a lower temperature. This process results in a dense and homogeneous material with good mechanical properties. The sintering process is a key step in the production of various ceramic products such as high-temperature insulation, refractory materials, and electronic components. The use of this new sintering process can lead to significant improvements in the performance and cost-effectiveness of these products.


Nabeshima, T., Ogawa, S., Kameyama, T., Shiotsani, T., Takasu, Y., Sakurai, T., Hasegawa, M. and Hasegawa, T., Effects of


243 Ohno, M., Yamamoto, T., Kitajima, I., Ueki, S., WEB 1881 FU ameliorates impairment of working memory induced by scopoletine and cerebral ischemia in the three-panel runway task, Jpn. J. Pharmacol., 54 (1990) 53-60.


Further support for the idea that the piracetam nootropics are only of benefit in situations of mild to moderate dementia have been observed in patients suffering from Alzheimer’s disease [6], multi-infarct dementia after long-term treatment [12,13], but no benefit was observed in patients suffering from Alzheimer’s disease [6], multi-infarct or mixed dementia [2].

As concerning the mechanism of action of the piracetam-type nootropics, further support for an interaction of especially aniracetam with the AMPA receptor has appeared [15] (for a short review, see Nicoletti et al. [9]). Aniracetam reduces the anticonvulsant effect of non-NMDA antagonists, but not of NMDA antagonists and without being a convulsant itself [3]. This would seem to confirm the idea that the nootropics do not have any activity of their own, but only potentiate activity already present.

The modulatory effect on AMPA responses does, however, not completely explain the activity of aniracetam, since it has been observed that activation of the metabotropic glutamate receptor (mGluR) causes protection against AMPA, kainate and glutamate-induced neurotoxicity, an effect potentiated by aniracetam. Aniracetam seems to potentiate the mGluR-coupled stimulation of phospholipase C [10]. Furthermore, the modulatory effect on the AMPA receptor does not explain the peripheral effects observed with the piracetam-type nootropics.

Effects on LTP have also been reported. Augmentation is observed by aniracetam [1,14], whereas piracetam is without effect on LTP in the dentate gyrus in vivo [8]. Very interesting is the fact that (S)-oxiracetam has higher activity than (R)-oxiracetam in an LTP study [4]. This is the first observation of different activity of the enantiomers of oxiracetam.

Finally, micromolar concentrations of oxiracetam enhance the K+ -induced release of [3H]GABA, [3H]norepinephrine, and [3H]acetylcholine, but not [3H]HVA, or [3H]hydroxytryptamine [11], but, on the other hand, it has also been reported that aniracetam blocks N-type calcium channels [7], which are known to be involved in the release of transmitters.

Some of the ambiguities with aniracetam might be explained by the fact that aniracetam is quite unstable and may be subjected to metabolism by non-specific esterases/amidases, as rolziracetam is, yielding N-anisoyl-GABA, 4-methoxybenzoic acid and 2-pyrrolidone causing different effects.

We would finally like, once more, to encourage the use of (R)- and (S)-etiracetam and now also (R)- and (S)-oxiracetam in the search for the mechanism of action of these compounds.